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LeuO is a LysR-type transcriptional regulator that is conserved among many gram negative 
enteric pathogens. LeuO is a bifunctional regulator that is capable of both repression and 
activation of gene targets. The function of LeuO has been characterized in several members of 
the Enterobacteriaceae where it has been found to be a global regulator of diverse phenotypes, 
often by functioning as an H-NS antagonist. In this work we sought to characterize LeuO in 
Vibrio cholerae. RNA sequencing was used to identify LeuO regulated genes, many of which 
appeared to be involved in environmental adaptation. Interestingly, our results suggested that 
LeuO did not function as an H-NS antagonist in V. cholerae, but appeared to function 
redundantly with H-NS at many H-NS regulated promoters. In subsequent experiments, genetic 
approaches were used to confirm the RNA sequencing studies and to define the function of LeuO 
in V. cholerae adaptive responses. We found that LeuO was part of a complex regulatory cascade 
in which the one-component virulence regulator ToxR directly activated leuO expression in 
response to environmental cues. LeuO then went on to directly regulate genes that contributed to 
bile resistance, acid tolerance, and cationic antimicrobial peptide resistance. Our collective 
results suggest a model whereby LeuO contributes to temporal and spatial regulation of adaptive 
responses during V. cholerae passage through the host gastrointestinal tract. 
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1.0  INTRODUCTION 
1.1 CHOLERA 
Cholera is an acute diarrheal disease caused by the gram negative bacterium Vibrio cholerae 
(Reviewed in (1, 2)). There are a reported 1.4-4.3 million cholera cases every year which result 
in an estimated 28,000-142,000 deaths worldwide (3). Although an acute disease, cholera 
outbreaks are a major public health risk and can have widespread socioeconomic impacts. Fear 
of trade-sanctions and travel restrictions in locations with cholera often results in a lack of 
cholera reporting and in extreme instances a delay in the response of global disease response 
networks. Cholera is endemic in many regions of the world, particularly in developing regions. 
Cholera outbreaks are commonly associated with the displacement of large populations, for 
example following natural disasters, political turmoil, and war. 
1.1.1 Epidemiology 
There are more than 200 serogroups of V. cholerae based on the O-antigen of their 
lipopolysaccharide. The majority of V. cholerae serogroups can cause mild cases of diarrhea but 
are not capable of causing cholera epidemics. Only two V. cholerae serogroups have been 
documented to cause outbreaks: those exhibiting the O1 and O139 serogroup. The O139 
serogroup was first identified in Bangladesh in 1992 and subsequently spread to South America 
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(4). However, disease caused by the O139 serogroup has largely disappeared from South 
America and is now confined to South-East Asia. The O1 serogroup is responsible for the 
majority of cholera outbreaks and is further divided into two biotypes: the El Tor and classical 
biotypes. Historically, there have been seven recorded cholera pandemics (5). The first six 
pandemics were caused by classical strains between 1817 and 1923. The seventh pandemic, 
which is currently ongoing, began in 1961 and was caused by the El Tor strain. The disease 
cholera is endemic in around 50 countries most of which are in Asia and Africa. These countries 
have been linked to as the starting point of localized epidemic outbreaks as well as the pandemic 
spread of V. cholerae (6). Cholera epidemics are often attributed to a combination of poor 
sanitations, overcrowding, lowered immunity, and environmental factors such as seasonality or 
natural disasters. 
1.1.2 Transmission 
Cholera is typically found and spread in underdeveloped countries and areas with inadequate 
water treatment, poor sanitation, and improper hygiene. Cholera is transmitted through the 
ingestion of V. cholerae contaminated food or water. An infectious dose is roughly estimated to 
be between 105-108 colony forming units (7, 8). People infected with V. cholerae can become 
symptomatic or asymptomatic carriers. Approximately 4 out of 5 people infected with V. 
cholerae become asymptomatic carriers, where they do not develop disease symptoms, but the 
bacteria is present in their feces for 1-10 days after infection. People who are symptomatic shed 
the bacteria from 2-14 days after infection. Once disseminated back into the environment, human 
shed V. cholerae are thought to exist in a short-lived hyperinfectious state which contributes to 
transmission to a subsequent host (9).  
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1.1.3 Symptoms 
Following the ingestion of V. cholerae contaminated food or water, the onset of cholera 
symptoms can take between 2 hours and 5 days. The duration between ingestion and symptom 
development is dependent upon the initial inoculum (10). Among people who develop 
symptomatic cholera, 80% exhibit mild to moderate diarrheal symptoms. The remainder of 
symptomatic people develops typical severe disease symptoms which include a profuse watery 
diarrhea, vomiting, and muscle cramps. Depending upon the stage of disease, some patients will 
exhibit signs of dehydration. Cholera-related diarrhea, often referred to as rice-water stool, is 
rapid and immense with fluid losses of up to 1 liter per hour. This rapid loss of body fluids leads 
to dehydration and hypovolemic shock. Without treatment, death can occur within hours. 
1.1.4 Treatment and Prevention 
Cholera is a self-limiting disease that can be successfully treated with oral rehydration therapy. 
Oral rehydration therapy is based on the use of oral rehydration salts to replace fluid and 
electrolytes that are lost in the secretory diarrhea. Intravenous fluids are also administered to 
people exhibiting symptoms of severe dehydration. In some severe cases, patients are also 
administered antibiotics. Antibiotics have been shown to diminish the duration of diarrhea, 
reduce the volume of rehydration fluids needed, reduce bacterial shedding, and to reduce 
symptoms of the disease. Mass administration of antibiotics in epidemic and endemic settings is 
not recommended, as it has no effect on the spread of cholera and contributes to increasing 
antimicrobial resistance. 
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The main approach for the prevention of cholera is the provision of proper sanitation. 
However, as evidenced by the endemic nature of cholera in many parts of Asia, building 
sanitation infrastructure in developing countries has proven to be difficult. Only recently have 
preventative strategies using vaccines begun to be employed. Currently there are two WHO pre-
qualified oral cholera vaccines: Dukoral and Shanchol. Both vaccines are killed whole cell 
vaccines that contain O1 V. cholerae. Shanchol also contains O139, while Dukoral contains 
recombinant cholera toxin B subunit. Both vaccines have a two-dose regimen and require cold 
storage. Protection through vaccination has been shown to be effective but short lived with 
reduced efficacy in young children. The efficacy of these vaccines in epidemic outbreaks is 
currently being assessed in Haiti. Currently there are no countries that require cholera 
vaccination. 
1.2 VIBRIO CHOLERAE 
V. cholerae is a gram negative facultative human pathogen. In order to successfully cause the 
disease cholera, V. cholerae must enter into the host, overcome host defenses, colonize host 
tissue, release cholera toxin, and then disseminate back into the aquatic environment.  
1.2.1 V. cholerae in the environment 
The natural reservoir for V. cholerae is the aquatic environment; V. cholerae can be found in 
estuaries, brackish waters, and oceans in many areas of the world. V. cholerae can be isolated 
from aquatic reservoirs as individual free-living cells (i.e. planktonic cells), or in biofilms 
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associated with aquatic organism or abiotic surfaces. The population dynamics of V. cholerae in 
the aquatic ecosystem is influenced by a multitude of environmental factors (Reviewed in (11)). 
Algae blooms have been correlated with increased prevalence of V. cholerae in the environment, 
presumably due to the increase in nutrient availability. Seasonal rainfall has been shown to affect 
V. cholerae distribution in the environment. It is even proposed that global warming has 
impacted water temperature and acidification which has influenced the prevalence of V. cholerae 
in aquatic reservoirs. The ever changing aquatic ecosystem requires V. cholerae be able to adapt 
to a multitude of environmental conditions.  
1.2.2 Host defenses  
V. cholerae enters the human host through ingestion of V. cholerae contaminated food or water. 
Passage of V. cholerae through the gastrointestinal tract exposes the cells to a number of host 
defenses (Reviewed in (12)). V. cholerae must first survive passage through the gastric acid 
barrier of the stomach. Surviving bacteria then enter the lumen of the small intestine where they 
are exposed to high concentrations of bile acids and other organic acids plus products of the 
resident flora. V. cholerae then must migrate through the mucus layer, where they encounter 
products of the innate immune system including antimicrobial peptides and antibodies. V. 
cholerae has evolved a number of responses to mitigate the effects of these host defenses. 
Common mechanisms with which bacteria can combat these stressors include: altering their 
outer membrane, the efflux of harmful substrates, enzymes that chemically degrade or inactivate 
antimicrobials, and mutations in DNA that change gene products which are targets of the 
antimicrobials (13).  
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1.2.3 V. cholerae virulence factors 
Once V. cholerae has entered the small intestine it traverses the mucous layer and migrates 
towards the epithelial surface where it produces attachment factors that facilitate colonization 
and replication (12). Early during V. cholerae infection, virulence factors are produced which 
contribute to colonization and disease development. Two of the major virulence factors produced 
by V. cholerae is cholera toxin (CT) and the toxin-coregulated pilus (TCP). CT is an AB-type 
enterotoxin consisting of a single A subunit and five B subunits (Reviewed in (14, 15)). The B 
subunit binds to GM1 gangliosides that are located on the surface of epithelial cells to deliver the 
A subunit. The A subunit then enters into the host cytoplasm before being activated by the 
reduction of a disulfide bond which releases the active A1 subunit. The A1 subunit then ADP-
ribosylates Gsα, a GTP-binding regulatory protein that is associated with adenylate cyclase. 
ADP-ribosylation of Gsα leads to constitutive cyclic AMP production (cAMP). High 
concentrations of cAMP then increase chloride and bicarbonate secretion while inhibiting 
sodium chloride uptake which then results in osmotic water loss into the intestinal lumen. The 
massive water secretion into the lumen produces the hallmark secretory diarrhea that is 
characteristic of the disease cholera. The TCP is a Type IV pilus that has been shown to be 
essential for intestinal colonization (16). While the TCP is not required for adherence to 
enterocytes, it has been shown to be required for microcolony formation in vivo (17). In addition 
to CT and TCP there are a number of accessory toxins and accessory colonization factors that 
contribute to V. cholerae pathogenesis.  
While V. cholerae virulence factors have been shown to be induced upon host entry, 
recent studies have shown that virulence factors are repressed late in infection prior to 
dissemination in the diarrheal purge (18, 19). Late in infection V. cholerae also induces the 
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expression of other genes which are largely unknown that contribute to dissemination and 
transmission (20). The regulatory mechanisms controlling this phenotype shift late in infection 
have not been defined. 
1.3 THE TOXR REGULON 
V. cholerae major virulence factors, CT and TCP, are under the control of a hierarchical 
regulatory cascade called the ToxR regulon (Reviewed in (21)). Production of virulence factors 
require the proper conditions, as such, many of the proteins in this cascade are influenced by 
environmental stimuli (22). Inside the intestines, fine-tuned regulation and spatial-temporal 
regulation of virulence factors is critical. There are three primary transcriptional regulators in the 
ToxR regulon: ToxT, TcpP, and ToxR. The ToxR regulon has been further subdivided into 
ToxT-dependent and ToxT-independent branches. The ToxT-dependent branch is responsible for 
producing CT and TCP (Fig. 1) while the ToxT-independent regulates the production of outer 
membrane porins and the downregulation of the ToxR regulon in response to environmental cues 
(Fig. 2). 
1.3.1 The ToxT-dependent branch 
The virulence factors CT and TCP are under direct control of ToxT. ToxT is an AraC-like 
transcriptional activator that regulates expression of the genes ctxAB and tcpA-F operons which 
encode CT and TCP, respectively (23). ToxT activity at its target promoters has also been shown 
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to be influence by environmental factors including bicarbonate and fatty acids. The expression of 
toxT is coordinately regulated by ToxRS and TcpPH (24).  
ToxR is a transmembrane transcriptional regulator and a one-component signal 
transducing protein (25). ToxR has an amino-terminal cytoplasmic DNA-binding domain and a 
carboxy-terminal periplasmic domain. The periplasmic domain of ToxR is able to sense 
environmental signals and alter the DNA-binding activity of the cytosolic DNA binding domain. 
ToxR directly interacts with ToxS, another transmembrane localized protein. ToxS has been 
shown to stabilize ToxR and is necessary for optimal ToxR transcriptional activity (26, 27). 
ToxR activity at its target promoters has been shown to be influence by a variety of 
environmental stimuli including peptides and bile salts (25, 27-29).  
TcpP is a ToxR-family transmembrane transcriptional regulator (30). TcpP directly 
interacts with TcpH, another transmembrane localized protein. TcpH has been shown to be 
responsible for protecting TcpP from proteolytic degradation (31). In the absence of TcpH, TcpP 
is rapidly degraded which may play a role in downregulation of the ToxR regulon late in 
infection. TcpP activity, like ToxR, is also thought to be influenced by environmental stimuli 
including bile salts (32). Expression of tcpPH is coordinated regulated by AphA and AphB; two 
unlinked cytoplasmic regulatory proteins (33, 34). AphA is a member of the winged-helix family 
of transcription factors while AphB is a LysR-type transcriptional regulator. The expression of 
aphA and activity of AphB are also influence by environmental stimuli. The expression of aphA 
is under control of the V. cholerae quorum sensing systems while AphB activity is influenced by 




Figure 1. The ToxT-dependent branch of the ToxR regulon. 
The ToxT-dependent branch of the ToxR regulon is a cascade that controls production of cholera toxin (CT) and the 
toxin coregulated pilus (TCP). Porins are located in the outer membrane (OM) while the transmembrane proteins 
ToxR, ToxS, TcpP, and TcpH are located in the inner membrane (IM). AphA, AphB, and ToxT are all cytoplasmic 
transcriptional regulators. 
1.3.2 The ToxT-independent branch 
V. cholerae produces two major outer membrane proteins: OmpU and OmpT. OmpU and OmpT 
are general diffusion porins which are responsible for allowing the diffusion of nutrients, 
metabolites, and signaling molecules into and out of the cell (37). The genes encoding for OmpU 
and OmpT are reciprocally regulated by ToxR which binds to conserved direct repeat elements 
that are located in the ompU and ompT promoters (38, 39). ToxR positively regulates ompU and 
negatively regulates ompT. OmpU is preferentially produced during growth in rich media or in 
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minimal media containing certain amino acids, bile, or mucin (40). In nutrient poor 
environments, or in a toxR mutant strain, the porin profile is reversed and OmpT becomes 
predominant while OmpU is no longer produced. Consistent with activation of ompU expression 
by bile salts, the production of OmpU is associated with bile salt resistance while the production 
of OmpT is associated with bile salt susceptibility; a phenotype that is related to the pore 
properties of each respective porin (41). OmpU and OmpT production has been found to be 
regulated in response to different environmental stimuli including bile, osmolality, organic acids, 
cyclic dipeptides, and amino acids (28, 29, 40, 42).  
LeuO is a new member of the ToxT-independent branch of the ToxR regulon in V. 
cholerae. Recent studies in our laboratory showed ToxR activated leuO expression in response to 
an endogenously produced cyclic dipeptide cyclo(Phe-Pro) (43). Overexpression of leuO was 
then linked to downregulation of the ToxR regulon and attenuated production of CT and the 
TCP. These studies also showed that cyclo(Phe-Pro) signaling was dependent on the ToxR 
periplasmic domain; a finding that supported the conclusion that the ToxR periplasmic domain 
functioned in environmental sensing. The fact that cyclo(Phe-Pro) accumulated in culture 
supernatants at high cell density (29), such as occurs late in infection, suggested a model 
whereby ToxR may mediate the expression of genes late in infection in response to accumulated 
cell metabolites. Collectively the results of this study provided the first evidence that ToxR could 
function as a virulence repressor and suggested leuO functioned downstream of ToxR to 




Figure 2. The ToxT-independent branch of the ToxR regulon.  
The ToxT-independent branch of the ToxR regulon involves ToxR regulation of genes not essential for the 
production of cholera toxin (CT) or the toxin coregulated pilus (TCP). OmpU and OmpT are porins located in the 
outer membrane (OM) and are reciprocally regulated by ToxR. ToxR regulates LeuO, a cytoplasmic transcriptional 
regulator that represses CT and TCP production. The small molecule cyclo(Phe-Pro) (cFP) is one of the 
environmental signals that is directly sensed by ToxR and influences this regulatory cascade.  
1.4 LEUO 
LeuO is a LysR-type transcriptional regulator that is produced in many gram negative bacteria. 
LeuO is been best studied in the Enterobacteriaceae, where LeuO has been shown to be 
maximally expressed at high cell density and at stationary phase (44). LeuO was first 
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characterized in Salmonella enterica as being part of a promoter relay mechanism that 
functioned to regulate the expression of leucine biosynthesis genes (45, 46). Subsequent studies 
in the Enterobacteriaceae have suggested that LeuO is a global regulator that regulates the 
expression of diverse genes (47, 48). LeuO is also a bifunctional regulator, capable of regulating 
targets through repression or activation.  
1.4.1 LysR-type transcriptional regulators 
The LysR-type transcriptional regulators (LTTRs) are the largest family of bacterial genetic 
regulators (Reviewed in (49)). LTTRs have an N-terminal DNA binding domain with a winged 
helix-turn-helix motif, a long linker domain, and a C-terminal effector-binding domain. Although 
the DNA-binding domain is well conserved amongst LTTRs, the consensus binding sequence is 
not well defined and contains an AT-rich region with imperfect dyad symmetry. There are 38 
LTTRs annotated in the V. cholerae genome, this large number can give insight as to why there 
is little conservation in binding sequences amongst LTTRs. With theoretically many LTTRs 
produced in one cell at any given time, specificity for target genes requires that each protein have 
its own unique characteristics. The multimeric state of LTTRs also contributes to specificity with 
the majority of LTTRs being found to function as tetramers. This conformation implies that 
LTTRs are able to regulate transcription through bending of the DNA. Dimerization is often 
achieved through the linker domain. The effector-binding domain is divided into two 
subdomains with a co-inducer binding cleft between them. Co-inducer binding is a common way 
in which substrates are used in feedback loops to regulate LTTR protein activity. Co-inducers 
have been found to also increase the LTTRs affinity for DNA or alter the degree of DNA-
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bending. There are often homologs of an LTTR protein amongst bacteria that are structurally and 
functionally similar but regulate diverse cellular processes based on the respective organisms. 
1.4.2 Roles of LeuO in the Enterobacteriaceae 
LeuO function is well characterized in a number of Enterobacteriaceae. In both Escherichia coli 
and S. enterica serovar Typhimurium, LeuO has been shown to function as an antagonist of H-
NS, the histone-like nucleoid structuring protein (47, 48). H-NS is a small chromatin-associated 
global transcriptional silencer found in Enterobacteriaceae (50). Approximately one half of the 
LeuO gene targets were shown to overlap with H-NS targets; however, H-NS is not required for 
LeuO binding and LeuO does not displace H-NS from the DNA.  
LeuO has been shown to regulate a multitude of different phenotypes in the 
Enterobacteriaceae. In E. coli LeuO has been shown to regulate citrate fermentation, fimbriae 
production, and biofilm production (48). LeuO was also shown to be upregulated in response to 
low phosphate, branched amino acid starvation, and in response to the stringent response 
alarmone guanosine pentaphosphate (ppGpp) (44, 51, 52). In S. enterica LeuO has been shown 
to regulate virulence genes including OmpS1 and OmpS2 porins, and genes in the Salmonella 
pathogenicity island I (53-55).  
LeuO also appears to be a global regulator in the family Vibrionaceae where it has been 
linked to diverse phenotypes. For example, in V. parahaemolyticus, LeuO has been shown to 
regulate the expression of a type III secretion system and cell swarming (56, 57). In V. vulnificus, 
LeuO has been shown to regulate cell wall degradation and in V. cholerae LeuO has been linked 
to biofilm production and virulence factor production (43, 58, 59). 
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1.5 GOALS OF DISSERTATION 
ToxR is a global regulator that has been shown to regulate the expression of its target genes in 
response to a variety of environmental stimuli; a phenotype that is exemplified by the function of 
ToxR in activating virulence gene expression following host entry. Studies from our laboratory 
recently showed that ToxR could also repress virulence gene expression at high cell density via 
activation of leuO expression. This observation suggested the possibility that ToxR may function 
to regulate the V. cholerae host exit program or to regulate V. cholerae adaptive responses to the 
dynamic environments found in the host gastrointestinal tract. Since LeuO functioned 
downstream of ToxR, and has been shown to regulate diverse genes in other bacteria, we 
hypothesized that LeuO plays an important role in regulating the expression of adaptive 
responses in V. cholerae. This work sought to characterize the function of LeuO in V. cholerae.  
The goal of Chapter 2 was to investigate the relation between LeuO and bile resistance. I 
found that leuO transcription increased in response to bile and bile salts, but not in response to 
other detergents. The bile-dependent increase in leuO expression was contingent on ToxR which 
was found to bind directly to the leuO promoter. I further showed that the periplasmic domain of 
ToxR was required for basal leuO expression and for the bile-dependent induction of both leuO 
and ompU transcription. V. cholerae mutants that did not express leuO exhibited increased bile 
susceptibility suggesting that LeuO contributes to bile resistance. My collective results 
demonstrated that ToxR activated leuO expression in response to bile and that LeuO was a 
component of the ToxR-dependent responses that contribute to bile resistance. In this work I 
showed that the function of ToxR in bile resistance extended beyond porin regulation to include 
leuO.  
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The goal of Chapter 3 was to investigate the relationship between LeuO and acid 
tolerance. V. cholerae is a neutrophilic enteric pathogen that is extremely sensitive to acid. As V. 
cholerae passages through the host gastrointestinal tract it is exposed to a variety of 
environmental stresses including low pH and volatile fatty acids. Exposure to acidic 
environments induces expression of the V. cholerae acid tolerance response. A key component of 
the acid tolerance response is the cad system, which is encoded for by cadC and the cadBA 
operon. CadB is a lysine/cadaverine antiporter and CadA is a lysine decarboxylase which 
function together to counter low intracellular and extracellular pH. CadC is a membrane 
associated transcription factor that activates cadBA expression in response to acidic conditions. I 
investigated the role of the LysR-type transcriptional regulator LeuO in the V. cholerae acid 
tolerance response. Transcriptional reporter assays revealed that leuO expression repressed cadC 
transcription, indicating that LeuO was a cadC repressor. Consistent with this, leuO expression 
was inversely linked to lysine decarboxylase production and leuO overexpression resulted in 
increased sensitivity to organic acids. Overexpression of leuO in a cadA mutant potentiated 
killing by organic acids suggesting that the function of leuO in the acid tolerance response 
extended beyond its regulation of the cad system. Collectively, these studies have identified a 
new physiological role for LeuO in V. cholerae acid tolerance. 
The goal of Chapter 4 was to investigate the relationship between LeuO and resistance to 
cationic antimicrobial peptides (CAMPs). Antimicrobial susceptibility screens revealed that leuO 
deletion resulted in increased resistance to polymyxin B. Polymyxin B is cationic peptide-like 
antibiotic. The polymyxin B mechanism of action, like other CAMPs, is related to its function in 
disruption of cell membranes. The initial binding of CAMPs to gram negative bacteria is 
mediated by electrostatic interactions between the positively charged CAMP and the negatively 
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charged lipopolysaccharide (LPS). As such bacteria have evolved mechanisms to resist the 
bactericidal effects of cationic antimicrobial peptides by altering the charge of their LPS via 
chemical modification. In V. cholerae the genes encoded by the almEFG operon have been 
shown to be required for CAMP resistance. The AlmEFG proteins function to modify V. 
cholerae lipid A with glycine and diglycine. This modification changes the charge of the 
lipopolysaccharide, making it more electropositive and thus reducing the electrostatic 
interactions with CAMPs. The almEFG operon is positively regulated by the CarRS two-
component system. CarR is the response regulator and CarS the environmental sensor with 
downstream targets being regulated in response to polymyxin B and bile. I investigated whether 
LeuO affected CAMP resistance through regulating the expression of carRS. I showed through 
transcriptional reporter assays and gel shift assays that LeuO was a direct repressor of carRS. V. 
cholerae mutants that did not express leuO exhibited increased resistance to polymyxin B, and 
conversely overexpression of leuO made cells more susceptible to polymyxin B. My collective 
results demonstrated that LeuO contributed to cell surface remodeling and polymyxin B 
resistance through the regulation of carRS. 
One of the goals of my thesis was to test the hypothesis that LeuO was a global regulator 
in V. cholerae. To test this, I utilized RNAseq to define the LeuO transcriptome (Appendix B). 
The results of this experiment confirmed that LeuO was a global regulator in V. cholerae. I found 
that LeuO affected the expression of 113 genes with 80 being repressed and 33 being activated 
by LeuO. The RNAseq analysis showed that in addition to regulating genes involved in acid 
tolerance, CAMP resistance, biofilm and pathogenesis, LeuO also regulated genes involved in 
cell metabolism and a number of stress responses.  
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2.0  VIBRIO CHOLERAE LEUO TRANSCRIPTION IS POSITIVELY REGULATED 
BY TOXR AND CONTRIBUTES TO BILE RESISTANCE 
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Vibrio cholerae is a gram-negative bacterial pathogen and the causal agent of the severe 
diarrheal disease cholera. V. cholerae exists naturally in aquatic reservoirs and is capable of 
colonizing the human small intestine. The transition of V. cholerae from the aquatic ecosystem to 
growth in the human gastrointestinal tract is mediated by transcriptional responses that are 
required for colonization and disease development. Many of the genes that contribute to 
intestinal colonization are under control of the membrane associated regulatory protein ToxR; 
which functions as one of the primary regulators in the ToxR regulon (Reviewed in (21)). The 
ToxR regulon is divided into two branches, a ToxT-dependent branch which controls the 
expression of virulence factors, and a ToxT-independent branch which reciprocally regulates the 
production of outer membrane porins OmpU and OmpT. The ToxT-dependent branch of the 
ToxR regulon is a hierarchical regulatory cascade that regulates the expression of genes 
encoding for the production of cholera toxin (CT) and the toxin co-regulated pilus (TCP) in 
response to environmental cues in the host. 
ToxR is a membrane associated regulatory protein that belongs to the winged-helix 
family of transcriptional regulators (60, 61). ToxR is a one-component signal transducing protein 
that is composed of a periplasmic signaling domain and a cytoplasmic DNA binding domain that 
are linked by a single transmembrane spanning domain (25). toxR is encoded in an operon along 
with toxS which is located downstream of toxR. ToxS is an inner membrane protein, which is 
thought to interact with ToxR to facilitate its transcriptional activity (26, 27). The ToxR 
periplasmic signaling domain is thought to sense and transduce environmental stimuli to affect 
the activity of the cytoplasmic DNA binding domain at its target genes. ToxR has been shown to 
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respond to a variety of environmental stimuli including acidity, nutrient availability, salinity, 
small molecules, and bile (25, 28, 29, 42).  
It has been shown that ToxR plays an essential role in modulating adaptive responses that 
contribute to bile resistance. Bile is produced by the liver and secreted at high concentrations into 
the small intestine to aid in the digestion of lipids. Bile is composed primarily of bile salts, but 
also contains significant amounts of phospholipids, cholesterol, protein and bilirubin. While bile 
is important in digestion, bile also provides a barrier against intestinal colonization by restricting 
bacterial growth in the small intestine; presumably through its detergent-like effects on bacterial 
cell membranes (62). As such, enteric pathogens have evolved methods to overcome this barrier. 
This includes the modulation of outer membrane porin proteins to decrease the rate of diffusion 
of toxic molecules across the outer membrane and by the expression of active efflux systems 
which remove bile salts from within the cell envelope (63-67). In V. cholerae, resistance to the 
antimicrobial effects of bile is due to the combined action of multiple factors including active 
efflux and ToxR regulated genes. This is evident by the observation that toxR mutant strains 
exhibit greatly increased susceptibility to bile and bile salts (68). 
The elevated susceptibility of toxR mutant strains to bile salts has been linked to the 
expression of the ompU and ompT porins (68). OmpU and OmpT are general diffusion porins 
located in the outer membrane. Porins are responsible for allowing the diffusion of nutrients, 
metabolites, and signaling molecules into and out of the cell (37). OmpU and OmpT have been 
found to be regulated in response to environmental stimuli including bile, osmolarity, organic 
acids, cyclic dipeptides, and amino acids (25, 28, 29, 42). The genes encoding for OmpU and 
OmpT are reciprocally regulated by ToxR; which binds to conserved direct repeat elements that 
are located in the ompU and ompT promoters (38, 39). ToxR positively regulates ompU and 
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negatively regulates ompT. OmpU is preferentially produced during growth in rich media or in 
minimal media containing certain amino acids, bile, or mucin (40). In nutrient-poor 
environments, or in a toxR mutant strain, the porin profile is reversed and OmpT becomes 
predominant while OmpU is no longer produced. Consistent with activation of ompU expression 
by bile salts, the production of OmpU is associated with bile salt resistance while the production 
of OmpT is associated with bile salt susceptibility (41). This phenotype is presumably related to 
the fact that OmpU, in contrast to OmpT, is an anion selective porin which restricts passage of 
negatively charged compounds (41, 69).  
Previous studies in our laboratory suggested that in V. cholerae ToxR activated leuO 
expression in response to cFP (43). Increased leuO transcription was linked to down regulation 
of the ToxR regulon and attenuated CT and TCP production. These results suggested that leuO 
functioned downstream of ToxR to modulate gene expression in response to environmental cues. 
LeuO is a LysR-family transcription factor that was first identified as a regulator of leucine 
biosynthetic genes in Salmonella typhimurium (45). Subsequent studies have shown LeuO to be 
a global regulator of diverse and unrelated phenotypes in the Enterobacteriaceae. For example, 
in Salmonella enterica LeuO has been shown to regulate outer membrane proteins, virulence 
genes, transport genes, biofilm production, and quorum sensing (70). Likewise, LeuO has been 
shown to be involved in the regulation of genes involved in carbohydrate utilization, phage 
resistance, acid shock, temperature adaptation and biofilm production in Escherichia coli (48). 
LeuO has also been associated with virulence gene regulation in Yersina enterocolitica (71). The 
function of LeuO as a global regulator appears to be conserved in the Vibrionaceae where LeuO 
has been shown to contribute to biofilm production, cell wall degradation, and virulence gene 
regulation (43, 57-59).  
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Since bile acids are an important environmental cue during V. cholerae pathogenesis, and 
since ToxR regulates the expression of many of its target genes in response to bile salts, we 
tested the hypothesis that leuO expression was also modulated in response to bile via ToxR. The 
results of our experiments showed that leuO expression was activated upon exposure to bile salts 
by a mechanism that was dependent on ToxR. Multiple approaches were used to show that ToxR 
acted directly at the leuO promoter and that the ToxR periplasmic domain was required for basal 
leuO expression and the bile-dependent induction of both leuO and ompU expression, 
respectively. Mutants that failed to express leuO exhibited reduced survival upon exposure to 
lethal concentrations of bile, indicating that LeuO contributed to bile resistance. Collectively our 
results indicated that ToxR activated leuO and ompU expression in response to bile salts by a 
mechanism that was dependent on the ToxR periplasmic signaling domain and that LeuO 














Table 1. Strains, plasmids and oligonucleotides used in Chapter 2. 
Strain, plasmid or 
oligonucleotide Relevant characteristics Source 
Strains   
Escherichia coli   
EC100λpir supE44 ΔlacU169 (φ80 lacZΔM15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1 (λpirR6K) Epicenter 
SM10λpir thi-1 thr leu tonA lacY supE recA::RP4-2-Tc::Mu Kmr (λpirR6K) Lab collection 
   
Vibrio cholerae   
JB58 O1 El Tor strain N16961 ∆lacZ, SmR Lab collection 
XBV222 JB58∆leuO (43) 
DT733 JB58∆toxRS (43) 
SS4 JB58 toxR∆ppd This study 
   
Plasmids   
pCM10 luxCDABE reporter plasmid, KmR (72) 
pJB906 pCM10 containing the leuO promoter (43) 
pTL61T lacZ transcriptional reporter plasmid, CbR (73) 
pXB266 pTL61T containing the leuO promoter region with two ToxR binding sites  
pVA258 pTL61T containing the leuO promoter region with one ToxR binding site This study 
pVA261 pTL61T containing the leuO promoter region with no ToxR binding sites This study 
pXB233 pTL61T containing the vexRAB promoter (74) 
pXB228 pTL61T containing the vexEF promoter (75) 
pXB229 pTL61T containing the vexGH promoter (75) 
pXB230 pTL61T containing the vexIJK promoter (75) 
pXB231 pTL61T containing the vexCD promoter (75) 
pXB232 pTL61T containing the vexLM promoter (75) 
pBAD18 Arabinose regulated expression plasmid, CbR (76) 
pBAD33 Arabinose regulated expression plasmid, CmR (76) 
pXB298 pBAD18Km expressing leuO (43) 
pVA94 pBAD18 expressing leuO This study 
pXB289 pBAD18 expressing toxRS (43) 
pXB286 pBAD18 expressing toxR∆ppdS (43) 
pXB302 pBAD33 expressing toxRS This study 
pDT1391 pBAD33 expressing toxR∆ppdS This study 
pWM91 Suicide plasmid vector used for allelic exchange (77) 
pWM91::∆toxRppd pWM91 containing a fragment of toxR harboring a deletion of the periplasmic domain This study 
   
Oligonucleotides Sequence (5’ to 3’)  
PleuO1-F CGCCCGGGAAATGCATTTTTATAGATTTTT  
PleuO2-F CGCCCGGGAATCGTATTGATTATTAAGGCT  
PleuO-R GGGGATCCGCGTCTTTTTTATCTAACATTTGCATGCCT  
toxR∆ppd-F1 GGGAGCTCGGTCCTCAAAAGAGATAT  
toxR∆ppd-F2 CTGCTCACTAACTAGGATCTTGCTAT  
toxR∆ppd-R1 AACCCGGGCATGCCGCTCAGTCAGG  
toxR∆ppd-R2 AGCAAGATCCTAGTTAGTGAGCAGTA  
5’BIO GCGGGAGTCGGCAGCG  
leuO-F-EMSA GCGGGAGTCGGCAGCGGTTAAAACATTTTTGACGTGAATATTAGTG  
leuO-R-EMSA GCGGGAGTCGGCAGCGCGTCACTAGCGATAAATATGCATAAATC  
ompU-F-EMSA GCGGGAGTCGGCAGCGCAATTAGATTGCGTGCATTT  
ompU-R-EMSA GCGGGAGTCGGCAGCGTTTTTTTACTCCCAAAGTTC  
vexR-F-EMSA GCGGGAGTCGGCAGCGTGCAAAACAGGGGGTATTAG  
vexR-R-EMSA GCGGGAGTCGGCAGCGGCCGTACACTATTTCAGACA  
leuO-qPCR-F GACCACTTCGCCACAAATCACCA  
leuO-qPCR-R CGTTGGATGGCGGAAAATGCG  
ompU-qPCR-F ACACCGTATAGGCTGTCATTG  
ompU-qPCR-R GTGCTGAAGCTCGCCTATCTC  
gyrA-qPCR-F CAATGCCGGTACACTGGTACG  




2.2.1 Bile salts induce expression of leuO. 
In response to bile salts, ToxR has been shown to activate ompU and ctxAB expression while 
repressing ompT expression (68, 78). Given that ToxR activates the expression of at least some 
of its target genes in response to bile salts, we hypothesized that ToxR may also regulate leuO 
expression in response to bile salts. To test this hypothesis we introduced a leuO-lacZ reporter 
plasmid pXB266 into WT strain JB58. The resultant strain was then cultured in the presence of 
bile or the bile salt deoxycholate to middle logarithmic growth phase when leuO expression was 
quantified by the β-galactosidase assay. The results showed a ~5-fold increase in leuO 
expression in the presence of bile and a ~6-fold increase in leuO expression in the presence of 
deoxycholate compared to the LB broth control (Fig. 3A). These results confirmed the 
hypothesis that leuO expression was upregulated in the presence of bile or deoxycholate. 
Bile salts and other components of bile exhibit detergent-like properties that can affect 
the permeability barrier of the outer membrane and compromise the integrity of the cytoplasmic 
membrane (62). This alluded to the possibility that leuO was upregulated as a result of the 
deleterious effects from the detergent properties of bile/deoxycholate on the cell envelope. If this 
was true, we hypothesized that exposure of V. cholerae to other classes of membrane active 
detergents should also result in leuO upregulation. We therefore tested the effects of two anionic 
detergents (SDS and Sarcosyl) and one nonionic detergent (Triton X-100) on leuO-lacZ 
expression. The results showed that exposure of JB58(pXB266) to these three detergents did not 
significantly affect leuO expression (Fig. 3A). Taken together, these results suggested that leuO 
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induction was specific for bile and bile salts and was probably not a result of the detergent-like 
properties of bile or deoxycholate. 
The finding that bile salts induced leuO expression prompted us to investigate if cFP and 
bile salts functioned synergistically to regulate leuO expression. To test this we quantified leuO 
expression in WT strain JB58 containing pJB906 (leuO-lux) during growth in LB broth 
containing DOC, cFP, or DOC and cFP. As expected, the addition of DOC to the media activated 
leuO expression (Fig. 3B). However, the addition of cFP to the media did not significantly 
increase leuO expression compared to the DMSO control. cFP did activate leuO expression at 
high (non-physiological) concentrations of cFP (data not shown). As cFP was shown to activate 
leuO expression under AKI growth conditions, this result suggests that cFP activity is dependent 
on the growth conditions (43). The addition of both DOC and cFP to the growth media resulted 
in a small, but reproducible decrease in leuO expression compared to cells grown in media 
containing DOC and DMSO. Although the presence of DOC and cFP appeared to decrease leuO 
expression, the differences were not statistically significant. Based on these results we concluded 
that cFP and DOC do not work synergistically to increase leuO expression during growth under 
standard laboratory conditions. It remains to be determined how cFP and DOC affect leuO 




Figure 3. Induction of leuO transcription by bile and bile salts requires ToxR. 
Induction of leuO transcription by bile and bile salts requires ToxR. (A) WT strain JB58 carrying the leuO-lacZ 
reporter plasmid pXB266 was grown in LB broth or LB broth supplemented with bile or the indicated detergents. 
Culture aliquots were collected at middle logarithmic phase and assayed for leuO-lacZ expression by the β-
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galactosidase assay. (B) The expression of leuO-lux in WT strain JB58::pJB906 (leuO-lux) during growth in LB 
broth containing the indicated compounds. DOC was used at 0.0125%, cFP at 1 mM and DMSO at 0.1%. (C) WT 
strain JB58 and ∆toxRS strain DT733 carrying pXB266 (leuO-lacZ) were grown in LB broth or LB broth plus 0.2% 
bile or 0.1% deoxycholate. Culture aliquots were collected at middle logarithmic phase and assayed for leuO-lacZ 
expression by the β-galactosidase assay. The presented data are the mean +/- SD of three independent experiments. 
Statistical significance in panel A was determined using One-Way ANOVA with Dunnett’s post-test comparing 
each mean with the LB control; *=P<0.01. Statistical significance in panel B was determined using Two-Way 
ANOVA with Tukey’s post-test; *=<0.0001. Abbreviations: DOC, deoxycholate; TX-100, Triton X-100; SDS, 
sodium dodecyl sulfate; MU, Miller Units; DMSO, dimethyl sulfoxide; RLU, Relative Light Units. doi: 
10.1128/JB.00419-15. 
2.2.2 Upregulation of leuO by bile is dependent on ToxR. 
ToxR regulates OmpU and OmpT production in response to bile salts. This suggested the 
possibility that ToxR may be responsible for the bile-dependent upregualtion of leuO in response 
to bile and bile salts. To test this we compared leuO-lacZ expression in JB58(pXB266) and an 
isogenic ∆toxRS mutant DT733(pXB266) that had been cultured in the presence and absence of 
bile or deoxycholate as described above. The results showed that leuO expression in JB58 was 
increased on exposure to deoxycholate and bile relative to growth in LB alone (Fig. 3C) as 
shown above. In contrast, leuO expression in the ∆toxRS mutant grown in LB broth decreased by 
~15-fold relative to JB58. This indicates that ToxR is a positive regulator of leuO, confirming 
previous findings (43). Deletion of toxRS also abolished the bile- and deoxycholate-dependent 
upregulation of leuO (Fig. 3C). Together these data indicated that ToxR was required for basal 
leuO expression and for the increased leuO expression in response to bile and bile salts. Further, 
given that none of the other tested detergents affected leuO expression, we speculate that the 
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ToxR-dependent upregulation of leuO was specific for bile salts, and was not due to other 
components of bile or due to a general membrane stress response. 
2.2.3 ToxR acts directly on the leuO promoter. 
Previous studies showed that ToxR binds to direct repeat elements that represent a ToxR 
consensus binding sequence in the toxT, ompU, ompT, and ctxAB promoters to regulate their 
transcription (25, 38, 39, 79, 80). The gene encoding LeuO (VC2485) is encoded downstream 
from VC2486 in an apparent two-gene operon. Sequence analysis of the leuO promoter revealed 
the presence of two putative ToxR consensus binding sequences, suggesting that ToxR may 
directly regulate leuO expression (43). The distal ToxR binding site (i.e. site A in Fig. 4A) is 
located from -126 to -112 relative to the start codon for VC2486 while the proximal ToxR 
binding site (i.e. site B in Fig. 4A) is encoded on the complementary strand from -104 to -90 
relative to the start codon for VC2486. To determine if both ToxR binding sites were required 
for leuO expression, derivatives of the leuO promoter lacking one or both ToxR consensus 
sequences were transcriptionally fused to the lacZ gene in pTL61T. All together we generated 
three leuO-lacZ reporters: pXB266 (WT leuO promoter), pVA258 (deletion of the distal ToxR 
binding site), and pVA261 (no ToxR binding sites) (Fig. 4A).  
We introduced these three leuO-lacZ reporter plasmids into WT strain JB58 and the 
∆toxRS mutant strain DT733. The resulting strains were then grown to middle logarithmic phase 
when leuO-lacZ expression was quantified using β-galactosidase assays (Fig. 4B). Consistent 
with above data, the results of these tests showed high levels of β-galactosidase production in 
JB58 containing the native leuO promoter (i.e. pXB266) and very little β-galactosidase 
production in the ∆toxRS mutant containing the same promoter reporter. In contrast, very little β-
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galactosidase was produced in JB58 or the ∆toxRS mutant containing the leuO reporters lacking 
one (pVA258) or both (pVA261) ToxR consensus binding sites. These results confirmed that 
ToxR was required for leuO expression and suggested that sites A and B were both required for 
basal leuO expression in V. cholerae.  
We next tested to see if the addition of bile could bypass the requirement for both ToxR 
binding sites in the leuO promoter to induce leuO expression. We therefore cultured WT strain 
JB58 bearing the three leuO-lacZ reporter plasmids (Fig. 4A) in the presence and absence of bile 
and quantified leuO expression. The results showed that only the full-length leuO promoter (i.e. 
pXB266) supported the activation of leuO expression in the presence of bile (Fig. 4C). Very little 
β-galactosidase was produced in JB58 containing the leuO reporters lacking one (pVA258) or 
both (pVA261) ToxR consensus binding sites in the presence or absence of bile. These results 
indicated that both ToxR binding sites are required for the bile-dependent induction of leuO 
expression. 
The presence of the ToxR binding sequences in the leuO promoter suggested that ToxR 
acts directly on the leuO promoter. If this were true, we hypothesized that ToxR expression in a 
heterologous host would result in activation of the leuO promoter. To test this we expressed 
toxRS from the pBAD33 arabinose inducible promoter in an E. coli host that contained each of 
the three leuO-lacZ reporters described above (i.e. pXB266, pVA258 or pVA261). We cultured 
the recombinant strains to middle log phase in the presence of arabinose (to induce toxRS 
expression) before quantifying leuO-lacZ expression using β-galactosidase assays. The results 
showed that expression of toxRS from pBAD33::toxRS resulted in high and equal expression 
from the native leuO promoter (pXB266) and the promoter lacking the distal ToxR binding site 
(pVA258) (Fig. 4D). β-galactosidase production was greatly diminished in the strain bearing the 
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leuO promoter that lacked both ToxR consensus sequences (pVA261). The ~18-fold increase in 
leuO-lacZ expression in the E. coli pBAD33::toxRS cultures bearing pXB266 and pVA258 
relative to the strain bearing pVA261 suggests that ToxR directly binds to the ToxR consensus 
binding sites in the leuO promoter to facilitate activation of leuO transcription in E. coli. These 
results also imply that in E. coli, in contrast to V. cholerae, ToxR can bind to the proximal ToxR 
consensus site in pVA258 to activate transcription. 
 
 
Figure 4. ToxR consensus binding sequences are required for ToxR activation of leuO transcription. 
(A) Schematic diagram of the leuO promoter in the indicated leuO-lacZ reporter plasmids. The location of the two 
putative ToxR consensus binding sites are indicated by the black boxes and denoted by the letters A (distal) and B 
(proximal). The putative -10 and -35 promoter elements are indicated by the white boxes. pXB266 contains the 
native leuO promoter which contains both ToxR consensus binding sites; pVA258 contains only the proximal ToxR 
binding site; and pVA261 lacks both ToxR binding sites but still maintains the -35 and -10 basal promoter elements. 
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(B) WT strain JB58, ∆toxRS strain DT733, and toxR∆ppd strain SS4 containing the indicated leuO-lacZ reporter 
plasmid were grown in LB broth to middle logarithmic phase when aliquots were collected and assayed for leuO-
lacZ using the β-galactosidase assay. (C) WT strain JB58 containing the indicated leuO-lacZ reporter plasmids were 
grown in LB broth or LB broth plus 0.2% bile to middle logarithmic phase when aliquots were collected and 
assayed for leuO-lacZ expression using a β-galactosidase assay. (D) E. coli strains containing the indicated toxRS 
expression plasmid pBAD33::toxRS, pBAD33::toxR∆ppdS, or pBAD33 and one of the leuO-lacZ reporter plasmids 
pXB266, pVA258 or pVA261 were grown in LB broth containing 0.08% arabinose to middle logarithmic phase 
when aliquots were collected and assayed for leuO-lacZ expression using the β-galactosidase assay. Statistical 
analysis for panel B was determined using Two-way ANOVA with Dunnett’s post-test comparing the mean of each 
plasmid to the control pTL61T in the designated strain; Panel C statistical analysis was determined using Two-way 
ANOVA with Tukey’s post-test comparing the overexpression plasmid to the pBAD33 control plasmid with the 
designated second plasmid; *=P<0.05, **=P<0.0001. doi: 10.1128/JB.00419-15. 
2.2.4 Activation of leuO requires the ToxR periplasmic domain. 
The periplasmic domain of ToxR was shown to be important for the cFP-dependent activation of 
leuO expression (43), but dispensable for basal ompU expression and virulence factor production 
(43, 60). We therefore examined whether the ToxR periplasmic domain contributed to leuO 
expression during growth in LB broth. To test this we generated a V. cholerae mutant (SS4) that 
produced a toxR allele in which we deleted the carboxy-terminal periplasmic domain (i.e. 
ToxR∆ppd). This mutant allele is localized to the membrane and was previously shown to be 
functional (43, 60). We then introduced pXB266, pVA258 and pVA261 into the toxR∆ppd mutant 
SS4. The strains were then cultured as described above when leuO-lacZ expression was 
quantified. The results showed that deletion of the ToxR periplasmic domain largely abolished 
leuO expression from all three leuO-lacZ reporters (Fig. 4B). This indicated that the ToxR 
periplasmic domain was important for leuO expression.  
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We also tested whether the ToxR periplasmic domain was necessary for activation of 
leuO expression in E. coli. E. coli strains containing each of the leuO-lacZ reporter plasmids 
were transformed with plasmid pBAD33::toxR∆ppdS (pXB286) and the resulting strains were 
cultured as described above before being assayed for leuO-lacZ expression. The results of these 
experiments mirrored the results obtained with E. coli expressing the WT toxRS allele. 
Overexpression of toxR∆ppdS from pXB286 activated both, the WT leuO promoter in pXB266 
and, the leuO promoter lacking the distal ToxR binding site in pVA258, to similar levels (Fig. 
4D). Further, the magnitude of activation was similar to that observed with the strain expressing 
the WT toxRS allele. This suggested that toxR∆ppd allele produces a functional protein that is able 
to bind to the ToxR consensus sequences in the leuO promoter and to activate leuO transcription. 
This suggests that the inability of ToxR∆ppd to activate leuO expression in V. cholerae was not 
due to its inability to bind to DNA, but rather due to other factors that are dependent on the 
presence of the ToxR periplasmic domain.  
2.2.5 ToxR can directly bind the leuO promoter. 
To further support the conclusion that ToxR bound directly to the leuO promoter, gel 
electrophoretic mobility shift assays were performed with the leuO promoter. The EMSAs were 
performed with crude membrane fractions that were isolated from V. cholerae strain DT733 
(∆toxRS) containing pBAD18 or pBAD18 expressing toxRS or toxR∆ppdS. As has been found 
with other gel shift assays using ToxR membrane fractions, the bound DNA probes do not enter 
the gel and are left in the wells of the gel, thus the binding of ToxR to the labelled probe should 
be assessed by the disappearance of free probe and not by the presence of a shifted band (61). 
The results showed that the ToxRS positive membrane fractions bound directly to the leuO 
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promoter which resulted in a decrease in the abundance of free leuO probe (Fig. 5A, lane 2). The 
decrease in free leuO probe was largely abolished in the presence of ToxRS negative membrane 
fractions (lane 7). Taken together these results indicated ToxR can directly bind to the leuO 
promoter.  
To determine whether ToxR binding to the leuO promoter was specific, we performed 
binding competition assays by including a 10-fold excess of unlabeled competitor DNA in the 
binding reactions. If ToxR bound specifically to the leuO promoter fragment, adding in excess 
unlabeled leuO promoter would prevent a shift in the free probe. When excess leuO DNA was 
added in the assay, there was a reduced shift in the labeled leuO probe (Fig. 5A, lane 3). The 
leuO promoter was also competed with a known ToxR specific promoter, ompU, which 
competed for leuO binding and prevented the shift in the free probe (lane 4). The addition of a 
non-specific competitor encompassing the vexR promoter, which is not regulated by ToxR, did 
not alter the level of free leuO probe (lane 5) indicating that the observed shift was specific for 
the leuO promoter. These same binding conditions were also used for ToxRS negative 
membranes (Fig. 5A, lanes 6-10). The results showed that although there was some decrease in 
free probe between the no protein control and the ToxRS negative membrane control, the 
decrease was much less than observed with ToxRS positive membranes and was unaffected by 
the addition of any of the unlabeled competitor probes. These results confirmed the specificity of 
the ToxR positive membranes for the leuO promoter. 
Gel shift assays were also performed to determine if deletion of the ToxR periplasmic 
domain altered ToxR binding to the leuO promoter. These experiments were performed as 
described above with membrane fractions from DT733 containing pBAD18 expressing 
toxR∆ppdS. The results showed that the ToxR∆ppdS membranes had comparable shifts as those of 
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the ToxRS membranes. The ToxR∆ppdS membrane fractions shifted the leuO promoter (Fig. 5B, 
lane 2). The leuO shift was competed by the addition of 10-fold excess unlabeled leuO or ompU 
promoter probes, but not by the addition of the nonspecific vexR promoter probe (lanes 3-5). 
These same binding conditions were also used for ToxR∆ppdS negative membranes (Fig. 5B, 
lanes 6-10). The results showed a decrease in free probe between the no protein control and the 
ToxR∆ppdS negative membrane control, but the decrease was much less than observed with 
ToxR∆ppdS positive membranes and was unaffected by the addition of any of the unlabeled 
competitor probes; confirming the specificity of the ToxR positive membranes for the leuO 
promoter. From these results we concluded that the ToxR periplasmic domain was not required 




Figure 5. ToxR and ToxR∆ppd interact with the leuO promoter. 
A biotinylated DNA fragment encompassing the leuO promoter was incubated with V. cholerae cytoplasmic 
membrane fractions isolated from strain DT733 (∆toxRS) that overproduced ToxRS or ToxR∆ppdS from pBAD18 
described in the Materials and Methods. The negative control membranes are ToxRS negative and were isolated 
from DT733 containing the empty vector control (i.e. pBAD18). The binding reactions contained either no 
membranes (lane 1 and 6) or equal amounts of the indicated membranes (lanes 2-5 and 7-10). Unlabeled competitor 
DNA probes encompassing the leuO, ompU or vexR promoters were added as indicated to the binding reaction at a 
10-fold excess relative to the biotinylated leuO DNA probe. Equal aliquots of binding reaction mixtures were then 
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electrophoresed on nondenaturing 5% acrylamide gels and the position of the leuO probe was visualized by 
chemiluminescence detection as described. (A) ToxR binding to the leuO promoter. The ToxR binding mixture 
contained 3 mg/ml of ToxRS positive membranes while control binding reactions contained an equivalent amount of 
ToxRS negative membranes. (B) ToxR∆ppd binding to the leuO promoter. The ToxR∆ppd binding mixture contained 1 
mg/ml of ToxR∆ppdS positive membranes while control binding reactions contained an equivalent amount of ToxRS 
negative membranes. The asterisks denote an unknown nonspecific mobility shift. doi: 10.1128/JB.00419-15. 
2.2.6 The ToxR periplasmic domain is important for responding to bile. 
The role of the ToxR periplasmic domain in environmental sensing is poorly understood. ToxR 
inversely regulates the ompU and ompT expression. OmpT is expressed during growth in 
minimal media while OmpU is expressed during growth in rich media. The addition of bile salts 
or the amino acids asparagine, arginine, glutamic acid, and serine (NRES) to minimal media 
results in ToxR-dependent porin switching that mimics growth in rich media (i.e. expression of 
ompU and repression of ompT) (77). The mechanism by which ToxR activates ompU expression 
in minimal media differs for bile salts and NRES (40). The addition of NRES to minimal media 
results in toxR upregulation which is sufficient to increase ompU expression. In contrast, bile 
salts activate ompU expression via a process that does not result in toxR upregulation and may 
involve transcriptional activation (40).  
We took advantage of ompT/ompU switching system described above to test the 
contribution of the ToxR periplasmic domain on leuO and ompU expression in response to bile. 
We cultured WT strain JB58, ∆toxRS strain DT733 and the toxR∆ppd strain SS4 in T-minimal 
media or T-media containing bile or NRES and quantified leuO and ompU expression by qRT-
PCR. The results showed that leuO expression was induced ~24-fold in response to bile and 
unaffected by the addition of NRES in the WT strain (Fig. 6A). The addition of NRES or bile to 
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the media did not affect leuO expression in the toxRS or toxR∆ppd mutants. By contrast to leuO, 
ompU expression increased in response to both NRES (13-fold) and bile (22-fold) relative to the 
control cultures (Fig. 6B). The expression of ompU was abolished under all conditions in the 
∆toxRS mutant. The expression of ompU in the toxR∆ppd mutant following exposure to NRES 
increased to a level that was similar to that observed in WT, further confirming that the toxR∆ppd 
allele produced a functional protein in V. cholerae. The expression of ompU in the toxR∆ppd 
mutant following exposure to bile resulted in a much lower level of ompU induction than was 
observed in WT. Exposure to bile resulted in a ~21-fold increase in ompU expression in WT, but 
only a ~3-fold increase in the toxR∆ppd mutant (Fig. 6B). Taken together, these results provide 
additional evidence that the ToxR∆ppd protein is functional and that the periplasmic domain of 
ToxR is critical for the induction of ompU and leuO in response to bile. This suggests the 




Figure 6. The ToxR periplasmic domain is required for leuO and ompU upregulation in response to bile. 
qRT-PCR was used to determine the effect of the amino acids NRES and bile on (A) leuO and (B) ompU expression 
during growth of JB58 (WT), DT733 (∆toxRS), and SS4 (toxR∆ppd) in modified T-media. The strains were cultured 
to an OD600 ~0.3 before being transferred to media supplemented containing either 50 mM NRES or 0.2% bile. The 
cultures were then grown for an additional 15 minutes before aliquots were collected for RNA isolation as described 
in the Materials and Methods. The presented data is the mean +/- SD of three independent experiments. Statistical 
significance was determined using a one-sample t test comparing the sample mean to a hypothetical value of +/-1; 
*=P<0.01. doi: 10.1128/JB.00419-15. 
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2.2.7 LeuO contributes to V. cholerae bile resistance. 
Since ToxR functions in bile resistance (28, 68), we hypothesized that LeuO may also contribute 
to V. cholerae bile resistance. To test this we performed bile killing assays. In these experiments 
we quantified the survival of WT V. cholerae (JB58) and isogenic leuO, toxRS, toxR∆ppd deletion 
mutants upon exposure to a lethal concentration of bile for one hour as described in the Materials 
and Methods (Appendix A). The results of these experiments showed a ~4-fold decrease in the 
recovery of the leuO mutant strain XBV222 relative to WT strain JB58 when exposed to 20% 
bile (Table 2). This suggested that the presence of leuO provided a survival advantage to V. 
cholerae in the presence of bile. The ∆toxRS mutant strain DT733 and the toxR∆ppd mutant SS4 
were not recovered when exposed to 20% bile. This finding is consistent with the role of ToxR in 
bile resistance and is likely attributable to the combined dysregulation of ompU, ompT and leuO 
expression in the ∆toxRS mutant. We therefore performed the killing assays with the toxR mutant 
strains using 10% bile. When exposed to 10% bile, the ∆toxRS mutant strain exhibited a ~11-fold 
decrease in recovery relative to WT; suggesting that the ∆toxRS mutant was more sensitive to 
bile than the ∆leuO mutant. The toxR∆ppd mutant exhibited a ~7-fold decrease in recovery 
compared to WT. This indicated that the toxR∆ppd mutant exhibited greater susceptibility to bile 
than did a ∆leuO mutant. As ToxR∆ppd has previously been shown to be sufficient for ompU 
expression under standard laboratory conditions, these results suggest the possibility that the 
periplasmic domain is required for expression of other factors, in addition to leuO, that could 
contribute to bile resistance. 
The above data suggested that LeuO contributed to V. cholerae survival in the presence 
of bile. If this was true, then overexpression of leuO in a ∆toxRS mutant should provide a 
survival advantage upon exposure to a lethal concentration of bile. We tested this by introducing 
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pBAD18-leuO or pBAD18 into the ∆toxRS mutant DT733. We chose a ∆toxRS mutant for these 
experiments to negate leuO and ompU expression. We cultured the toxRS deletion strain bearing 
the pBAD18-leuO plasmid pVA94 or the empty vector control (pBAD18) to log phase in the 
presence of 0.1% arabinose to induce leuO expression. Aliquots of the induced cultures were 
then exposed to lethal concentration of bile before being processed as described above. The 
results showed that leuO overexpression resulted in a ~5-fold increase in cell recovery relative to 
the empty vector control (Table 2). This indicated that LeuO contributed to V. cholerae survival 
in the presence of bile by a mechanism that is likely independent of ompU. Taken together the 
results of these experiments confirm the importance of ToxR in bile resistance and support the 
conclusion that ToxR-activation of leuO expression contributes to bile resistance. 
 
Table 2. Bile killing assays. 
  Fold change in recovery (SD) 
Strains:  10% bile 20% bile 
∆leuO/WT  1 -4.5 (2.1)a 
∆toxRS/WT  -11.3 (3.7)a NRb 
toxR∆ppd/WT  -7.0 (1.4)a NR 
∆toxRS pBAD18::leuO/∆toxRS pBAD18  5.2 (1.4)a NR 
a P < 0.01; b NR = Not Recovered; SD = standard deviation 
doi: 10.1128/JB.00419-15. 
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2.2.8 LeuO does not contribute to bile resistance through regulation of the RND efflux 
pumps. 
Our laboratory has previously shown that the V. cholerae RND-family efflux systems are major 
contributors to V. cholerae bile resistance (63-67). We therefore tested whether the contribution 
of leuO to bile resistance was mediated by upregulation of any of the RND efflux systems. We 
quantified the expression of all six of the RND efflux pumps in WT strain JB58 and the ∆leuO 
mutant strain XBV222 in response to bile using lacZ promoter reporter fusions. The strains were 
cultured in the absence or presence of bile to middle logarithmic growth phase when expression 
of the individual RND efflux systems was quantified. The results showed that in the absence of 
bile there were no significant differences in expression of any of the RND efflux pumps in the 
∆leuO mutant compared to the WT strain (Fig. 7). This indicated that LeuO did not contribute to 
the basal expression of any of the efflux pumps. When the same reporter strains were cultured in 
the presence of bile, as expected, vexRAB and vexCD expression were found to be significantly 
induced. However, there were no significant differences found in any of the RND efflux pumps 
expression between the WT and leuO deletion strain in response to bile (Fig. 7). This indicated 
that LeuO does not regulate the expression of the RND efflux systems and is not likely working 




Figure 7. Effect of leuO on the expression of the V. cholerae RND efflux systems. 
V. cholerae WT strain JB58 and ∆leuO mutant strain XBV222 carrying lacZ promoter fusion reporter plasmids for 
(A) vexRAB-lacZ (pXB233), (B) vexCD-lacZ (pXB231), (C) vexEF-lacZ (pXB228), (D) vexGH-lacZ (pXB229), (E) 
vexIJK-lacZ (pXB230) or (F) vexLM-lacZ (pXB232). All strains were cultured in LB broth in the presence or 
absence of 0.2% bile before being assayed for β-galactosidase activity as described in the Materials and Methods. 
The presented data is the mean +/- SD of three independent experiments. doi: 10.1128/JB.00419-15. 
2.3 DISCUSSION 
The ability of V. cholerae to respond to its environment is essential for its success as an enteric 
pathogen. This is critical upon entrance into the human host where V. cholerae must express 
genes that are indispensable for colonization of the small intestine. Colonization and growth in 
the small intestine requires the expression of virulence genes plus the expression of genes that 
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combat antimicrobial agents which are present in the intestine. ToxR plays a critical role in this 
regard by regulating the expression of genes that are required for host adaptation. ToxR is 
thought to transduce in vivo signals to effect the expression of its target genes, but the 
mechanism by which this occurs is poorly understood. 
In this study, we observed upregulation of leuO expression in response to bile and the 
bile salt deoxycholate by a process that was dependent on ToxR (Fig. 3). Bile salts have 
detergent-like properties which make them bactericidal. Expression of leuO was not altered by 
other membrane-active detergents (e.g. SDS, Triton X-100 or sarcosyl), indicating that leuO 
induction was not the result of general membrane stress response, but instead was directly in 
response to bile and bile salts. The upregulation of leuO in response to bile suggested the 
possibility that leuO may function in bile resistance. Support for this conclusion was provided by 
the observation that leuO deletion resulted in increased bile susceptibility while leuO over 
expression resulted in increased bile resistance (Table 2). In light of recent studies showing leuO 
is expressed in the intestine using an infant mouse model (43), we speculate that the findings 
observed here may extend to the host. These results were also similar to what has been reported 
for OmpU, a porin that is associated with bile resistance in V. cholerae and whose expression is 
also activated by ToxR in response to bile and deoxycholate (68). 
While the contribution of leuO to bile resistance is clear, the mechanism by which leuO 
impacts bile resistance was not resolved. The ∆leuO mutant strain exhibited a bile susceptibility 
phenotype that was intermediate relative to the ∆toxRS mutant (Table 2). This suggested that 
LeuO likely affected bile resistance by a mechanism that was distinct from ompU/ompT 
regulation. This conclusion was confirmed by the finding that leuO overexpression provided a 
survival advantage in a toxRS negative strain exposed to bile (Table 2). Bile resistance results 
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from the synergistic affects of reduced outer membrane permeability and active efflux (66). In V. 
cholerae the RND efflux systems are major contributors to bile resistance suggesting a potential 
mechanism by which LeuO could affect bile resistance. However, our results showed that there 
was no difference in the expression of any of the RND efflux systems in a leuO mutant grown in 
the presence or absence of bile (Fig. 7) suggesting that leuO affects bile resistance by a 
mechanism that is independent of the RND efflux systems. There are a number of other potential 
mechanisms by which LeuO could impact bile resistance including the expression of other 
transport systems, production of other porins, alterations in cell physiology, and alterations to the 
cell envelope.  
The expression of leuO was previously found to be dependent on ToxR (43). Sequence 
analysis of the leuO promoter revealed the presence of two putative ToxR consensus binding 
sites, both of which were required for basal-level leuO expression in V. cholerae (Fig. 4B). This 
finding was reminiscent of what was observed for ToxR activity at the ompU promoter where the 
most distal ToxR binding site was needed for full ompU activation in V. cholerae (39). By 
contrast, ToxR activated expression from the leuO promoter lacking the distal ToxR binding site 
(i.e. pVA258) in E. coli (Fig. 4D). The lack of expression from the same mutant promoter in V. 
cholerae suggested that other factors affect leuO expression in V. cholerae. We do not know 
what these factors are, but there are a number of potential explanations for this result. It is 
possible that other DNA binding proteins interact with the leuO promoter and impede ToxR 
binding at the proximal site. It is also possible that ToxR may bind sequentially to the two ToxR 
binding sites in V. cholerae, having to bind to the distal site first which then facilitates binding at 
the proximal site. This tandem fashion of binding is similar to other DNA-binding domains of 
OmpR-family proteins which generally interact as dimers with direct repeat DNA sequences 
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(80). This idea is also supported by cooperative binding studies comparing ToxR oligomerization 
and regulation of target promoters containing multiple operator elements in E. coli and V. 
cholerae (81). 
The periplasmic domain of ToxR has been implicated in responding to environmental 
signals, but how ToxR regulates its target genes in response to these signals is poorly 
understood. The finding that the ToxR periplasmic domain was required for the upregulation of 
both leuO and ompU in response to bile (Fig. 6) suggested the possibility that the periplasmic 
domain acts as a bile sensor which can affect the activity of the cytoplasmic DNA binding 
domain at its target promoters. The mechanism by which the periplasmic domain senses bile is 
unclear. There are a number of potential mechanisms by which bile could affect ToxR activity. 
Bile could facilitate ToxR interaction with ToxS. ToxS has been shown to contribute to ToxR 
stability and to enhance its activity at target genes (25-27). Alternatively, bile could potentially 
affect conformational changes in the ToxR periplasmic domain that affect DNA binding. Bile 
could also affect disulfide bond formation in the two cysteine residues located in the ToxR 
periplasmic domain. There is evidence that disulfide bond formation in the periplasmic domain 
of ToxR and ToxR-like proteins affect their activity. For example, disulfide bond formation in 
ToxR has been shown to contribute to ompU regulation in response to some growth conditions 
(82). ToxR and TcpP have also been shown to form homodimers and heterodimers (83, 84) and 
the bile salt taurocholate has been shown to induce intermolecular disulfide bond formation in 
the periplasmic domain of TcpP (32). Similarly, E. coli CadC has been shown to form disulfide 
bonds in response to pH which result in activation of cadBA transcription (85). Additional work 
will be required to differentiate between these potential mechanisms.  
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Previous studies showed that cFP activation of leuO resulted in the downregulation of the 
ToxR regulon (43). The data presented herein show that leuO expression is also activated by bile 
and bile salts. While the fatty acid components of bile have been linked to downregulation of the 
ToxR regulon (86), bile salts have been shown to either be neutral or to enhance virulence gene 
expression (32, 78). Thus, the role of LeuO in virulence gene regulation is a paradox. Although 
there are a number of potential explanations for the differential effects of LeuO on virulence, we 
suspect that bile salts and CDPs differentially affect the expression (or activity) of other proteins 
that contribute to virulence gene expression. For example, bile salts and cFP may differentially 
affect HNS or CRP; both of which have been shown to suppress the ToxR regulon and thus 
could contribute to the observed phenotype (87, 88). Studies to resolve the role of LeuO in 
virulence gene regulation are ongoing in our laboratory. 
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3.0  THE LYSR-TYPE REGULATOR LEUO REGULATES THE ACID TOLERANCE 
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Vibrio cholerae is a neutrophilic bacterium that is extremely sensitive to even mild acidic 
conditions (89). V. cholerae naturally persists in aquatic reservoirs with a neutral pH, variable 
nutrient availability, and ambient temperatures. V. cholerae is also an enteric pathogen that 
encounters a variety of environmental stresses while passing through the human gastrointestinal 
tract. Following ingestion V. cholerae encounters a dramatic change in pH from near neutral pH 
to a pH ≤ 2 in the human stomach. Passage of V. cholerae from the stomach into the small 
intestine further exposes the bacterium to an environment that contains a combination of 
inorganic acids and organic acids (90). Exposure of V. cholerae to acidic conditions results in the 
induction of an acid tolerance response. The acid tolerance response can be divided into two 
distinct branches: an inorganic acid tolerance response and an organic acid tolerance response 
(91).  
The V. cholerae acid tolerance response encompasses diverse genes that function together 
to mitigate the effects of acid stress. This includes alterations in the outer membrane, the 
expression of genes that function in the regulation of K+ and Na+ homeostasis, and biofilm 
production (42, 92, 93). The acid tolerance response is likely an important factor for V. cholerae 
pathogenesis. For example, biofilm production has been shown to enhance acid tolerance which 
contributes to pathogenesis by providing protection from acid stress during passage through the 
gastric acid barrier of the stomach (93, 94). In addition, pre-activation of the V. cholerae acid 
tolerance response has been shown to impart a competitive advantage for colonization of the 
infant mouse intestine relative to unadapted cells (91). Taken together these results suggest that 
the acid tolerance response may play a crucial role in the both initial infection with V. cholerae 
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and the subsequent development of hyper-infectivity that has been observed in human and 
animal shed V. cholerae (9, 95, 96). 
An important subset of genes that are induced in both the V. cholerae inorganic and 
organic acid tolerance response is the cad system. The contribution of the cad system to acid 
resistance is conserved among a number of enteric bacteria (97). The cad system includes three 
genes that are involved in maintaining the intracellular pH while also neutralizing the external 
pH. CadC is a ToxR-family transcriptional regulator that positively regulates the expression of 
the cadBA operon (98). CadA is a lysine decarboxylase that converts lysine to cadaverine while 
consuming a proton and producing carbon dioxide. CadB is a lysine-cadaverine antiporter that is 
localized to the cytoplasmic membrane. Tight regulation of the cad system is necessary as 
alterations in the intracellular pH is detrimental to the cell (99). 
In V. cholerae it has been shown that AphB, a cytoplasmic DNA-binding protein, 
positively regulates the cad system in response to low pH or low oxygen by directly binding to 
the cadC promoter (36). Upregulation of the cad system contributes to the maintenance of the 
intracellular pH. The expression level of the cad system returns to a low constitutive level upon 
neutralization of the external environmental. The molecular mechanism by which V. cholerae 
downregulates the cad system are not known. In Escherichia coli, the cad system is repressed in 
two ways: the first is through feedback inhibition by cadaverine, the second is through the 
transcriptional regulator LeuO which functions by repressing cadC expression (100). In V. 
cholerae cadaverine does not repress the cad system (91), but it is unknown if LeuO influences 
cadC expression.  
LeuO is a LysR-type transcriptional regulator that shares 50% identity and 75% similarity 
to E. coli LeuO. Our laboratory has shown that V. cholerae leuO is positively regulated by the 
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virulence regulator ToxR, often in response to environmental signals (43, 101). Expression of 
leuO is induced by the endogenously produced cyclic dipeptide cyclo(Phe-Pro). In response to 
cyclo(Phe-Pro) LeuO has was shown to repress the production of essential virulence factors by 
downregulating the ToxR regulon. Expression of leuO is also induced by bile salts and 
contributes to V. cholerae bile resistance (101). Preliminary transcriptomic profiling experiments 
performed in our laboratory indicated that the cad system was differentially regulated in a V. 
cholerae leuO mutant, suggesting that that LeuO may regulate the cad system. In the present 
study, we expanded upon this observation and tested the hypothesis that LeuO functioned as a 
regulator of the V. cholerae cad system. The results of our studies showed that LeuO was a 
repressor of cadC expression and directly bound to the cadC promoter. LeuO was also shown to 
regulate the production of CadA (lysine decarboxylase) and to contribute to V. cholerae survival 
after exposure to organic acid. LeuO overproduction in a cadA mutant also resulted in increased 
acid sensitivity suggesting that that the contribution of LeuO to acid tolerance extends beyond 
the cad system. Taken together, our studies have identified a new physiological role for LeuO 










Table 3. Strains, plasmids and oligonucleotides used in Chapter 3. 
Strains Characteristics Source 
E. coli   
EC100λpir supE44 ΔlacU169 (φ80 lacZΔM15) hsdR17 recA1 endA1 gyrA96 thi-1 
relA1 (λpirR6K) 
Epicenter 
SM10λpir thi-1 thr leu tonA lacY supE recA::RP4-2-Tc::Mu kmR (λpirR6K) Lab collection 
BW25113 F- Δ(araD-araB)567 lacZ4787Δ::rrnB-3 LAM- rph-1 Δ(rhaD-rhaB)568 hsdR514 (102) 
ER2566 fhuA2 lacZ::T7 gene1 [lon] ompT gal sulA11 R(mcr- 73::miniTn10--TetS )2 [dcm] 
R(zgb-210::Tn10--TetS ) endA1 Δ(mcrCmrr)114::IS10 
New England BioLabs 
V. cholerae   
JB58 V. cholerae O1 El Tor strain N16961 ∆lacZ, SmR Lab collection 
XBV222 JB58∆leuO (43) 
XBV148 JB58∆aphB This study 
JB804 V. cholerae O1 El Tor strain C6706 SmR (103) 
XBV144 JB804 ∆lacZ This study 
VA412 XBV144 ∆leuO This study 
EC20568 C6706 Tn::VC2485 (leuO) (104) 
EC17926 C6706 Tn::VC0278 (cadA) (104) 
Plasmids   
pTL61T lacZ transcriptional reporter plasmid, CbR (73) 
pXB239 pTL61T containing the cadC promoter region This study 
pXB203 pTL61T containing the aphB promoter region (105) 
pBAD18 Arabinose regulated expression plasmid, CbR (76) 
pVA94 pBAD18 expressing leuO (101) 
pBAD18Km Arabinose regulated expression plasmid, KmR (76) 
pXB298 pBAD18Km expressing leuO (43) 
pBAD33 Arabinose regulated expression plasmid, CmR (76) 
pVA126 pBAD33 expressing leuO This study 
pWM91 Suicide plasmid vector used for allelic exchange (106) 
pDLT pWM91 containing a fragment of lacZ harboring an internal deletion (107) 
pWM91∆leuO pWM91 containing a fragment of leuO harboring an internal deletion  (59) 
pWM91∆aphB pWM91 containing a fragment of aphB harboring an internal deletion This study 
pMAL-c2 IPTG-inducible expression vector for fusion of proteins to MBP and cytoplasmic 
expression, CbR 
New England BioLabs 
pVA175 pMAL-c2 expressing leuO This study 
Oligonucleotides Sequence (5` to 3`)  
PcadC-F TTCTCGAGTCGGGCTATCGACTGTACGATG  
PcadC-R GTTCTAGACACCACACACCGATGAAGAGCGAAATTATAA  
aphB-F1 TTGGATCCGCCCCACGATGGCTCGCG  
aphB-F2 CGACTGGTTGTCACAAAGATCACCAGCCGGAAAAAGTGCGCCTG  
aphB-R1 GCGAGCTCCAGTGGGCGATATGGGCG  
aphB-R2 GGTGATCTTTGTGACAACCAGTCGAAAGAGGTTTAGGTCATCTAG  
LeuO-F CCCCCGGGTTAGATAAAAAAGACGCAATGAGTGCC  
LeuO-R CCTCTAGATAGAAACGTAGAATGAACAAAGGATC  
cadC-EMSA-F1 GCGGGAGTCGGCAGCGGATGGTTAAACAACCTAAGTT  
cadC-EMSA-R1 GCGGGAGTCGGCAGCGGAGCGAAATTATAAGTGCAC  
cadC-EMSA-F2 GCGGGAGTCGGCAGCGAATTTCGCTCTTCATCGGTG  
cadC-EMSA-R2 GCGGGAGTCGGCAGCGCATAGAATAGCTCTTTGTATC  




3.2.1 LeuO regulates cadC expression. 
Our preliminary transcriptome studies suggested the possibility that LeuO may regulate the V. 
cholerae cad system. The cad system is regulated by AphB, which functions as an activator of 
cadC. Once CadC is produced, it directly activates the expression of the cadBA operon. 
Therefore we tested if LeuO affected the expression of either of these two regulatory genes in V. 
cholerae. We first investigated cadC transcription by quantifying cadC expression levels in WT 
strain JB58 and an isogenic ∆leuO strain XBV222 using the cadC-lacZ transcriptional reporter 
pXB239. The test strains were cultured under AKI virulence gene inducing conditions and cadC-
lacZ expression was quantified using β-galactosidase assays. The results showed that cadC 
expression peaked at 5 hrs and declined thereafter (Fig. 8A). Growth of V. cholerae under AKI 
conditions results in the acidification of the culture media during static growth (i.e. the first four 
hours). The reduction in pH appears to correlate with the generation of organic acid byproducts 
from fermentation metabolism. After the initial 4 hrs of static growth, the cultures are shifted to 
aerobic growth which results in alkalization of the media (data not shown). Thus, cadC 
expression appeared to correlate with the changes in the pH of the growth medium during growth 
under AKI conditions. The expression of cadC in the ∆leuO mutant mirrored expression in the 
WT strain except that the expression level was elevated in the ∆leuO mutant compared to WT. 
The elevated cadC expression observed in the absence of leuO supported the hypothesis that 
LeuO was a regulator of the cad system and was acting as a repressor of cadC. 
If LeuO was a cadC repressor, then we hypothesized that leuO overexpression would 
repress cadC transcription in V. cholerae. To test this hypothesis V. cholerae WT strain JB58 
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was transformed with the expression plasmid pVA126 (pBAD33-leuO) and the cadC-lacZ 
reporter plasmid pXB239. The resulting strain was cultured under AKI growth conditions in AKI 
broth alone or AKI broth containing arabinose to induce leuO expression. Expression of cadC 
was then quantified at 5 hrs post-inoculation. The results showed that the induction of leuO 
expression by the addition of 0.02% arabinose resulted in a ~60% reduction in cadC expression 
(Fig. 8B). This finding further supported the conclusion that LeuO was a cadC repressor in V. 
cholerae.  
There are several potential mechanisms for LeuO to affect cadC expression. LeuO could 
act directly at cadC by binding to its promoter and inhibiting transcription. Alternatively, LeuO 
could repress cadC expression indirectly by repressing the expression of its upstream activator 
aphB. To differentiate between these two possibilities, we examined the effect of leuO 
overexpression on aphB transcription. We therefore repeated the above experiments using WT 
strain JB58 carrying pVA126 (pBAD33-leuO) and an aphB-lacZ transcriptional reporter plasmid 
(pXB203). The results showed that the induction of leuO expression by the addition of 0.02% 
arabinose did not alter aphB expression (Fig. 8B). This indicated aphB is not regulated by LeuO 




Figure 8. Effect of LeuO on cadC and aphB expression. 
(A) WT V. cholerae strain JB58 and ∆leuO strain XBV222 carrying the cadC-lacZ reporter plasmid pXB239 were 
grown under AKI conditions. Culture aliquots were taken at the indicated times and assayed for β-galactosidase 
activity as described in the Materials and Methods. The presented data is the mean +/- SD of three independent 
biological replicates. (B) WT strain JB58 bearing pBAD33-leuO plasmid pVA126 and either the cadC-lacZ 
transcriptional reporter pXB239 (black bars) or the aphB-lacZ transcriptional reporter pXB203 (grey bars) were 
grown under AKI conditions in the presence or absence of 0.02% arabinose. Expression of the indicated reporter 
gene was assessed at 5 hrs by measuring β-galactosidase production. The presented data is the mean +/- SD of three 
technical replicates and is representative of two independent experiments. Statistical significance was determined 
using a t-test comparing the sample mean to the WT control mean; *=P<0.05, **=P<0.01. doi: 
10.1099/mic.0.000194.  
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3.2.2 LeuO represses cadC expression by directly binding to its promoter. 
The above results suggested that LeuO reduced cadC expression independently of aphB, but did 
not discriminate between LeuO affecting cadC expression directly or indirectly. To address this 
we examined whether leuO expression affected cadC-lacZ expression in a heterologous host. We 
introduced both the pBAD33-leuO expression plasmid pVA126 and the cadC-lacZ reporter 
plasmid pXB239 into E. coli and quantified cadC-lacZ expression following growth in LB broth 
for 5 hrs in the presence and absence of arabinose. The results showed a ~65% decrease in cadC-
lacZ expression in LB broth containing 0.02% arabinose (Fig. 9A). This result indicated that 
genes unique to V. cholerae were not required for LeuO repression of cadC and suggested that 
LeuO may act directly at the cadC promoter. We note that these results do not exclude the 
possibility that LeuO could be acting indirectly through an intermediate gene present in E. coli.  
To confirm further that LeuO was acting directly at the cadC promoter we performed gel 
shift assays. For these experiments, we purified LeuO as a translational fusion to the maltose 
binding protein (MBP) and generated two biotin labeled DNA probes from the cadC locus. The 
first DNA probe, named cadC1, contained the cadC promoter region from -79 to +1 relative to 
the cadC transcriptional start site as defined by Merrell et al (98)(Fig. 9B). This region of the 
cadC promoter also included the AphB binding site which was mapped to nucleotides -71 to -55 
(36). The second DNA probe, called cadC2, was used as a negative control and contained 
nucleotides -8 to +77 relative to the cadC transcriptional start site. The results of the gel shift 
assays showed that LeuO-MBP bound to the cadC1 DNA probe, but not to the cadC2 DNA 
probe (Fig. 9B). Incubation of the cadC1 DNA probe with MBP alone did not result in a shift, 
confirming that LeuO was responsible for the shift of the cadC1 probe by the LeuO-MBP fusion 
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protein. Taken together these results confirmed that LeuO directly binds to a region in the cadC 
promoter that is present in the cadC1 probe. 
 
 
Figure 9. Influence of LeuO on the cadC promoter. 
(A) E. coli containing the cadC-lacZ reporter plasmid pXB239 and the pBAD33-leuO plasmid pVA126 was grown 
in LB broth in the presence or absence of 0.02% arabinose for 5 hrs when β-galactosidase activity was determined. 
The presented data is the mean +/- SD of three independent experiments. Statistical significance was determined 
using a t-test comparing the mean of the induced strain to mean of 0% arabinose control; *=P<0.005. (B) Gel shift 
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assays were performed using purified LeuO-MBP or MBP and the two indicated DNA fragments from the cadC 
promoter. Nucleotide numbering listed for the cadC1 and cadC2 DNA fragments are relative to the cadC 
transcriptional start site. Biotin labeled cadC1 or cadC2 DNA fragments (1.5 nM) were incubated with either 
purified LeuO-MBP or MBP at 0 μM (lane 1), 10 μM (lane 2), 20 μM (lane 3), or 30 μM (lane 4) prior to 
electrophoresis. doi: 10.1099/mic.0.000194. 
3.2.3 Lysine decarboxylase activity is influenced by LeuO. 
CadC positively regulates the expression of cadBA, and thus the production of lysine 
decarboxylase (CadA), in response to low environmental pH (98). Based on this, we 
hypothesized that if LeuO repressed cadC, then leuO deletion of should result in increased cadC 
expression, and a corresponding increase in cadBA expression and lysine decarboxylase 
production. Likewise, leuO overexpression should result in decreased cadC expression and a 
corresponding decrease cadBA expression and lysine decarboxylase activity. To test this 
hypothesis we quantified lysine decarboxylase activity in V. cholerae strains lacking leuO or 
aphB and in a V. cholerae leuO negative mutant in which we ectopically expressed leuO. In 
contrast to E. coli (108), V. cholerae only encodes one lysine decarboxylase (i.e. CadA) which 
facilitates direct measurement of lysine decarboxylase production in V. cholerae cell lysates as a 
reporter for cadA expression (91).  
We first quantified lysine decarboxylase production in WT strain JB58, ∆leuO strain 
XBV222, and ∆aphB strain XBV148. The results showed a 29% increase in lysine 
decarboxylase activity in the leuO mutant relative to WT (Fig. 10). Although this increase in 
lysine decarboxylase activity did not reach statistical significance (P=0.16), lysine decarboxylase 
activity was consistently elevated in the leuO mutant in multiple independent experiments. By 
contrast, deletion of aphB resulted in a 79% reduction in lysine decarboxylase activity. This was 
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expected, as AphB is a positive regulator of cadC. To provide further evidence that LeuO 
negatively regulated lysine decarboxylase production we quantified the effect of leuO 
overexpression from pBAD18Km-leuO (pXB298) on lysine decarboxylase production in a 
∆leuO mutant (XBV222). The results showed that the addition of 0.02% arabinose to the growth 
media resulted in a 53% reduction in lysine decarboxylase activity (Fig. 10). The observation 
that leuO deletion appeared to increase lysine decarboxylase activity, while leuO overexpression 
decreased lysine decarboxylase activity, provided additional evidence to support the conclusion 
that LeuO was a negative regulator of the cad system in V. cholerae. 
 
 
Figure 10. Impact of leuO on lysine decarboxylase production in V. cholerae. 
The WT strain JB58, ∆leuO strain XBV222, ∆aphB strain XBV148, and ∆leuO strain carrying the pBAD18Km-
leuO plasmid pXB298 were grown in AKI media under AKI conditions at 37°C for 4 hrs when lysine decarboxylase 
activity was quantified as described in the Materials and Methods. Strains containing the arabinose inducible 
pBAD18Km-leuO were grown in the presence or absence of 0.02% arabinose. Lysine decarboxylase specific 
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activity was defined as the amount of lysine converted to cadaverine per minutes divided by the optical density at 
600 nm. The presented data is the mean +/- SD of three independent experiments. * P=0.16; **P>0.05. doi: 
10.1099/mic.0.000194. 
3.2.4 Effect of LeuO on V. cholerae survival following organic acidic challenge. 
Studies have shown that the cad system contributes to an inducible acid tolerance phenotype 
whereby V. cholerae cells preadapted to mild acid conditions (i.e. pH 5.7) exhibit increased 
resistance to lethal acid challenge relative to unadapted cells (91). As our genetic and 
biochemical data suggested that LeuO repressed the cad system, we hypothesized that LeuO 
should also negatively affect V. cholerae acid tolerance (98). We tested this by challenging 
unadapted V. cholerae cells with varying concentrations of organic acids as described in the 
Materials and Methods (Appendix A). Since both leuO and the acid tolerance response were 
expressed in vivo (43, 92, 98), we chose to perform these assays using cells cultured under 
virulence gene inducing conditions (i.e. AKI conditions). We cultured WT, leuO, and cadA 
mutant strains for four hours under AKI conditions, which is the point where cadC expression 
was greatest (Fig. 8A), before exposing the cells to varying concentrations of organic acids that 
were present in the wells of microtiter plates. We then assessed cell viability at 15 and 30 
minutes post organic acid challenge with the unadapted cells and 45 and 60 minutes post 
challenge with the adapted cells by replica plating culture aliquots from the microtiter plates onto 
LB agar plates.  
The results for the unadapted cells revealed that there was no significant difference in the 
susceptibility of WT or the leuO mutant to organic acid challenge at either time point (Fig. 11A). 
This was an expected result given that LeuO appeared to be a cadC repressor. In contrast, the 
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cadA mutant exhibited an increase in susceptibility to the acid challenge as shown by decreased 
survival at 30 min relative to the WT control (Fig. 11A). This confirmed previous reports that 
cadA contributed to the V. cholerae acid tolerance response (91). In contrast to the unadapted 
cells, there was no apparent difference in organic acid susceptibility among any of the acid 
adapted mutant strains at either time point (Fig. 11B). This suggests that under virulence gene 
inducing conditions, other components of the acid tolerance response can compensate for the loss 
of cadA.  
LeuO is a global regulator in the Enterobacteriaceae; a phenotype that appears to be 
conserved in the Vibrionaceae. This suggested the possibility the LeuO might affect the 
expression of other acid tolerance genes in addition to cadC. If this were true, leuO 
overexpression in cadA mutant should result in increased organic acid susceptibility. To test this, 
we repeated the acid killing assays using leuO and cadA mutants in which we ectopically 
expressed leuO (Fig. 11C and 11D). The results showed that leuO overexpression in the leuO 
mutant resulted in increased susceptibility of the unadapted cells to organic acid challenge (Fig. 
11C). This finding confirmed that leuO expression enhanced V. cholerae susceptibility to organic 
acids and was consistent with the conclusion that LeuO repressed the cad system. Interestingly, 
ectopic expression of leuO in the cadA mutant also increased V. cholerae susceptibility to 
organic acid challenge (Fig. 11C). This finding indicated that the function of LeuO in organic 
acid tolerance extended beyond its regulation of the cad system.  
We next tested whether LeuO affected the induction of an acid tolerance response 
phenotype. We therefore repeated the above experiments with AKI cultures that had been 
preadapted at pH 5.7 for one hour prior to organic acid challenge. The results showed increased 
organic acid resistance among the adapted cells relative to the unadapted cells with all of the 
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tested strains (Fig. 11). This was supported by comparison of cell viability between the 30 min 
unadapted cultures and the 45 min adapted cultures. Significantly, 60 min post challenge, there 
were no observable difference in survival between the WT, leuO, and cadA mutant strains (Fig. 
11B) indicating that V. cholerae was able to mount an acid tolerance response in the absence of 
leuO and cadA. By contrast, when leuO was overexpressed in either the leuO or cadA mutants, 
the cells exhibited increased susceptibility to organic acid challenge relative to the empty vector 
control (Fig. 11D). This indicated that leuO overexpression negatively affected the ability of V. 
cholerae to mount an acid tolerance response. The fact that leuO overexpression in the cadA 
mutant resulted in increased acid susceptibility provided additional evidence to suggest that the 
function of leuO to acid tolerance extends beyond the cad system. 
 
 
Figure 11. Effect of leuO on V. cholerae survival in organic acid. 
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(A) Survival of unadapted WT (XBV144), leuO (VA412) and cadA (EC17926) following organic acid challenge for 
15 and 30 min. (B) Survival of adapted WT (XBV144), leuO (VA412) and cadA (EC17926) following organic acid 
challenge for 45 and 60 min. (C) Survival of unadapted leuO (EC20568) and cadA (EC17926) mutants containing 
pBAD18 or pBAD-leuO following organic acid challenge for 45 and 60 min. (D) Survival of adapted leuO 
(EC20568) and cadA (EC17926) mutants containing pBAD18 or pBAD-leuO following organic acid challenge for 
45 and 60 min. All strains were cultured for four hours under AKI conditions before the organic acid challenge; 
0.02% arabinose was added to the broth for strains containing pBAD18 or pBAD18-leuO. Unadapted cells (A and 
C) and adapted cells (B and D) were inoculated into microtiter plates containing the indicated final concentrations of 
the organic acid stock solution. The microtiter plates were then incubated at 37°C and cell viability was assessed 
over time by replica plating ~10 uL from each well of the microtiter plates onto the surface of an LB agar plate 
using a 96-well pin replicator. The agar plates were incubated overnight at 37°C before being photographed. The 
presented results are representative of at least three independent experiments. doi: 10.1099/mic.0.000194. 
3.3 DISCUSSION 
LeuO is a LysR-family regulator that has been shown to function downstream of ToxR in V. 
cholerae (43, 101). Several lines of evidence suggest that LeuO is a global regulator in the 
Vibrionaceae that functions in host adaptation and virulence. In V. cholerae LeuO has been 
shown to affect virulence factor production, biofilm production, and bile salt resistance (43, 59, 
101). In V. parahaemolyticus LeuO has been shown to regulate the expression of type III 
secretion system, and serine protease production in V. vulnificus (57, 58). Taken together these 
results suggest that LeuO likely functions to regulate diverse genes involved in environmental 
adaptation in the Vibrionaceae. 
In this work, we identified a new physiological function for LeuO in V. cholerae 
environmental adaptation. We found that LeuO regulated the expression of the cad system; a 
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finding that suggested that LeuO contributes to acid tolerance. The V. cholerae cad system is 
constitutively expressed at a low basal level, but is upregulated under conditions of low pH or 
low oxygen (36). Upregulation under these conditions is mediated by AphB binding to the cadC 
promoter. Once CadC is produced, it upregulates cadBA expression leading to the production of 
CadB (a lysine/cadaverine antiporter) and CadA (a lysine decarboxylase). CadA contributes to 
acid tolerance through its degradation of lysine to the polyamine cadaverine; a reaction that plays 
a key role in maintaining pH homeostasis within the cell.  
While AphB positively regulates expression of the cad system, our results showed that 
LeuO negatively regulates the expression of the cad system. This conclusion was supported by 
the fact that leuO deletion increased cadC expression while leuO overexpression reduced cadC 
expression (Fig. 8). These results strongly suggested that LeuO was a cadC repressor. The 
negative effects of leuO on cadC transcription were further shown to affect the production of 
lysine decarboxylase production, the downstream target of CadC (Fig. 10). Taken together these 
results indicated that LeuO negatively regulates the expression of the cad system by repressing 
cadC transcription.  
LeuO appeared to regulate the expression of the cad system by directly binding to the 
cadC promoter. This suggests the possibility that there may be interplay between AphB and 
LeuO in regulation of the cad system. Our results show that the expression of the cad system 
increased during static growth under AKI conditions before declining upon shift of the cultures 
to aerated growth (which is associated with alkalization of the media). Growth of El Tor strains 
under static AKI growth conditions results in low oxygen tension and low pH; conditions that 
have been correlated with AphB activation of cadC (36). By contrast, leuO expression appears to 
increase with cell density until it reaches its maximum level at late log phase (data not shown). 
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This suggests the possibility that LeuO may function to fine tune expression of the cad system by 
antagonizing AphB binding to the cadC promoter. The fact that both LeuO and AphB are LysR-
family regulators, and that LysR-family regulators bind to T-N11-A motifs (49), are consistent 
with this idea. Further, LeuO has been shown to regulate many of its target genes in the 
Enterobacteriaceae by functioning as an antagonist (48). Whether LeuO is functioning as an 
AphB antagonist in V. cholerae will require additional studies.  
Overexpression of leuO in a cadA mutant increased V. cholerae susceptibility to organic 
acid in both adapted and unadapted cells (Fig. 11). This suggested that the contribution of LeuO 
to organic acid tolerance extended beyond the cad system. The mechanism by which this 
occurred is not known. The acid tolerance response in V. cholerae is complicated and involves 
diverse genes including the virulence regulator ToxR (42, 92). ToxR was shown to be required 
for the organic acid tolerance response through its regulation of the OmpU and OmpT porins. 
The fact that ToxR positively regulates leuO expression suggests that the role of ToxR in acid 
tolerance extends beyond porin regulation. In addition to cadC, AphB positively regulates other 
genes that contribute to acid tolerance (36, 109). While LeuO does not appear to affect 
production of OmpU or OmpT (101), it is possible that LeuO could affect the expression of other 
AphB-regulated genes that contribute to acid tolerance via a mechanism similar to what occurs 
with cadC. Alternatively, given that LeuO appears to be a global regulator, LeuO could affect 
acid tolerance through regulation of other unknown genes.  
Although our data conclusively shows that LeuO represses cadC expression, the 
physiological relevance of LeuO repression of cadC and the acid tolerance response is not yet 
clear. Since leuO expression is induced by bile and LeuO contributes to bile salt resistance (101), 
one possibility is that downregulation of the acid tolerance response may contribute to bile 
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resistance. In S. typhimurium the acid tolerance response increased cell surface hydrophobicity 
(110); a phenotype that could result in increased susceptibility to detergent-like molecules like 
bile salts. If the V. cholerae acid tolerance response also resulted in increased cell surface 
hydrophobicity, leuO induction in response to bile salts may function to downregulate the acid 
tolerance response to decrease cell surface hydrophobicity and positively affect bile resistance. 
LeuO could also function in a feedback mechanism to modulate cadaverine production via cadC 
repression. Cadaverine is a polyamine that has two positive charges at neutral pH. Excess 
polyamines are growth inhibitory, which necessitates the regulation of their production (111). 
Cadaverine has also been found to reduce V. cholerae auto-agglutination, likely as a result of its 
positively charged amine groups electrostatically disrupting the pili interactions (112). Thus 
excess cadaverine could hinder intestinal colonization. 
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4.0  LEUO REGULATES THE CARRS TWO-COMPONENT SYSTEM AND IS A 
REPRESSOR OF POLYMYXIN B RESISTANCE IN VIBRIO CHOLERAE 
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Vibrio cholerae is a gram negative human pathogen and the causative agent of the diarrheal 
disease cholera. People acquire cholera by ingestion of food or water that is contaminated with 
V. cholerae. Following V. cholerae ingestion, the organism colonizes enterocytes in the small 
intestine and replicates to high cell titers in the intestinal lumen before being disseminated from 
the host in a secretory diarrhea. Within the human gastrointestinal tract, V. cholerae is exposed to 
a variety of antimicrobial compounds including products of the innate immune system like 
cationic antimicrobial peptides (CAMPs). V. cholerae resistance to these antimicrobial 
compounds is dependent upon the induction of adaptive mechanisms that include the 
upregulation of antimicrobial efflux systems, modification of cell permeability through porin 
production, and biochemical modification of the cell surface. 
 CAMPs are short (~12-50 amino acids) amphipathic peptides that typically contain an 
excess of basic amino acids that result in a net positive charge (Reviewed in (113)). In gram 
negative bacteria, electrostatic interactions between the positively charged CAMPs and the 
negatively charged lipopolysaccharide (LPS) are thought to drive the initial interaction of 
CAMPs with the cell surface. Binding of CAMPs to the LPS results in outer membrane 
perturbation which facilitates CAMP uptake. Once across the outer membrane, CAMPs can 
disrupt the cytoplasmic membrane and/or inhibit critical cytoplasmic processes resulting in cell 
death. V. cholerae has evolved a number of mechanisms to resist the antimicrobial effects of 
CAMPs. This includes active efflux of CAMPs that have traversed the outer membrane via the 
VexAB-TolC RND-efflux pump (64) and the induction of an extracytoplasmic stress response 
(114). Moreover, LPS modification has been shown to be critical for V. cholerae CAMP 
resistance. Production of hexacylated lipid A via the MsbB acyltransferase confers polymyxin B 
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resistance in V. cholerae (115). Glycine and diglycine modification of the LPS by AlmEFG has 
also been shown to confer high level polymyxin B resistance in V. cholerae (116). AlmEFG 
functions to add glycine to hexacylated lipid A. Glycinylation of lipid A results in a net positive 
charge on lipid A which is thought to reduce the electrostatic interactions between CAMPs and 
LPS and lead to CAMP resistance.  
CarRS was first identified in V. cholerae as a calcium-responsive negative regulator of 
biofilm production (117). Two subsequent studies have shown that CarRS also regulates cationic 
antimicrobial peptide resistance by positively regulating the expression of the almEFG operon 
(116, 118). Introduction of mutations into carR or the almEFG operon result in a ~100-fold 
decrease in V. cholerae resistance to the cationic-peptide like antibiotic polymyxin B. The 
molecular mechanisms controlling the expression of the carRS operon are unknown. Previous 
studies have shown that carRS expression is influenced by environmental cues (116). Growth of 
V. cholerae in the presence of polymyxin B resulted in upregulation of carRS, while growth in 
the presence of calcium or deoxycholate resulted in carRS repression.  
We have recently found a number of V. cholerae phenotypes that are regulated by LeuO, 
a LysR-type transcriptional regulator. Expression of leuO is positively regulated by ToxR, often 
in response to environmental stimuli. The small molecule cyclo(Phe-Pro) has been shown to 
induce leuO expression leading to LeuO-dependent repression of virulence factor production 
(43). Expression of leuO was found to be induced by bile salts with LeuO contributing to bile 
resistance (101). LeuO has additionally been considered to play a role in the acid tolerance 
response through its regulation of the cad system (119). Previous studies have identified LeuO as 
a positive regulator of biofilm production through a yet unknown mechanism (59).  
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In this study, we show through transcriptional reporter and gel shift assays that LeuO is a 
direct repressor of carRS. We found that repression of carRS by bile salts was dependent on 
LeuO. V. cholerae mutants that did not express leuO exhibited increased resistance to polymyxin 
B, and conversely overexpression of leuO made cells more susceptible to polymyxin B. Our 
collective results demonstrate that LeuO contributes cell surface remodeling and polymyxin B 
resistance through the regulation of carRS. 
 
Table 4. Strains, plasmids and oligonucleotides used in Chapter 4. 
Strain, plasmid or 
oligonucleotide 
Relevant characteristics Source 
Strains   
Escherichia coli   
EC100λpir supE44 ΔlacU169 (φ80 lacZΔM15) hsdR17 recA1 endA1 gyrA96 thi-1 
relA1 (λpirR6K) 
Epicenter 
SM10λpir thi-1 thr leu tonA lacY supE recA::RP4-2-Tc::Mu kmR (λpirR6K) Lab collection 
ER2566 F- glnV44(AS) galK2(Oc) rpsL704(strR) xylA5 mtl-1 argE3(Oc) thiE1 tfr-3 λ DE3 = λ 
sBamHIo ∆EcoRI-B int::(lacI::PlacUV5::T gene1) i21 ∆nin5 
New England BioLabs 
Vibrio cholerae   
JB3 V. cholerae O1 El Tor strain N16961, SmR Lab collection 
JB58 V. cholerae O1 El Tor strain N16961, SmR ∆lacZ Lab collection 
XBV222 JB58∆leuO (43) 
DT733 JB58∆toxRS (43) 
JB461 JB3∆toxRS (18) 
XBV302 JB58∆almE This study 
   
Plasmids   
pTL61T lacZ transcriptional reporter plasmid, CbR (73) 
pXB266 pTL61T containing the leuO promoter region (43) 
pVA289 pTL61T containing the carRS promoter region This study 
pMH53 pTL61T containing the carRS promoter region This study 
pBAD18Km Arabinose regulated expression plasmid, KmR (76) 
pXB269 pBAD18Km expressing VC2486 and leuO (43) 
pBAD33 Arabinose regulated expression plasmid, CmlR (76) 
pVA126 pBAD33 expressing leuO (119) 
pXB302 pBAD33 expressing toxRS (101) 
pMAL-c2 IPTG-inducible expression vector for fusion of proteins to MBP and cytoplasmic 
expression, CbR 
New England BioLabs 
pVA175 pMAL-c2 expressing leuO (119) 
pWM91 Suicide plasmid vector used for allelic exchange, CbR (106) 
pWM91::∆almE pWM91::∆VC1579 This study 
   
Oligonucleotides Sequence (5’ to 3’)  
PcarRS-F AAACTCGAGAACACGCGGCGAGGAATTGAGTCAG  
PcarRS-R CGGGGATCCGATAATGTAGAGACTGGGTTGG  
PcarRS-short-F CGCTCGAGGTTTAATCACTGAGAGTGTAGCC  
PcarRS-short-R GGGGATCCGTTGGTTAGACATGGGGACCTC  
almE-F1 CCCCCGGGCCACCAAGATACAAACTA  
almE-F2 TACAATTCTGCGGCGAGTCAGACATA  
almE-R1 ATGAGCTCGCTGCATCATGTCGGCTA  
almE-R2 TGTCTGACTCGCCGCAGAATTGTATG  
carRS-F-EMSA GCGGGAGTCGGCAGCGGGCGAGGAATTGAGTCAGAAGCC  
carRS-R-EMSA GCGGGAGTCGGCAGCGGAGACTGGGTTGGTTAGACATGGGG  
5’BIO 5`-biotin-GCGGGAGTCGGCAGCG  
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4.2 RESULTS 
4.2.1 LeuO regulates polymyxin B resistance in V. cholerae. 
Phenotypic screening of a V. cholerae leuO deletion strain for alterations in antimicrobial 
resistance indicated that the ∆leuO mutant exhibited an increase in resistance to cationic 
antimicrobial peptides. To confirm this phenotype, we determined the minimum inhibitory 
concentration (MIC) of a V. cholerae ∆leuO mutant on polymyxin B gradient agar plates. The 
results of these experiments revealed that deletion of leuO resulted in a ~3-fold increase in the 
polymyxin B MIC relative to WT (Table 5). This was surprising as the El Tor biotype of V. 
cholerae is intrinsically resistant to high concentrations of polymyxin B. We previously have 
shown ToxR positively regulated leuO expression (101). Therefore we also determined the 
polymyxin B MIC for a ∆toxRS mutant. The results showed that in contrast to the ∆leuO mutant, 
the ∆toxRS mutant exhibited a >2-fold decrease in the polymyxin B MIC relative to WT (Table 
5). This finding is consistent with the pleiotropic function of ToxR in polymyxin B resistance. 
ToxR is a global regulator that controls the expression more than 150 genes in V. cholerae (18) 
including the OmpU porin which has been linked to antimicrobial peptide resistance (120). The 
finding that mutation of toxRS resulted in a decrease in the polymyxin B MIC, while leuO 
mutation resulted in an increase in the polymyxin B MIC, suggests that porin dysregulation is 
dominant to leuO with respect to polymyxin B resistance. We also examined a ∆almE mutant. 
AlmE has been shown to be critical for the intrinsic polymyxin B resistance in V. cholerae (115). 
The ∆almE mutant exhibited a polymyxin B hypersensitive phenotype that was evidenced by a 
>100-fold decrease in its MIC. This finding was consistent with previous reports showing that 
the almEFG operon was required for cationic antimicrobial resistance. 
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The above data indicated that leuO negatively regulated polymyxin B resistance. If this 
was true, we hypothesized that leuO overexpression should result in increased V. cholerae 
susceptibility to polymyxin B. To test this, we compared polymyxin B susceptibility of WT and 
∆leuO V. cholerae in which we overexpressed leuO from the arabinose regulated promoter in 
pBAD18Km. The results of these experiments showed that leuO overexpression in WT reduced 
the polymyxin B MIC by ~3-fold relative to the empty vector control (Table 5). Likewise, leuO 
overexpression in the ∆leuO mutant resulted in a >5-fold decrease in the polymyxin B MIC 
relative to the empty vector control. The fact that leuO overexpression resulted in increased 
polymyxin B susceptibility in both WT and the ∆leuO mutant supported the hypothesis that leuO 
negatively regulated polymyxin B resistance in V. cholerae. 
 
Table 5. Polymyxin B susceptibility of V. cholerae strains. 
Strain MIC1 (sd) 
WT 114 (28.6) 
∆leuO 360 (2.1)2 
∆toxRS 50 (2.3)2 
∆almE < 3 (0)2 
WT (pBAD18Km) 118 (13.4) 
WT (pBAD18Km-leuO ) 40 (15.9)3 
∆leuO (pBAD18Km) 294 (45.6) 
∆leuO (pBAD18Km-leuO ) 56 (5.6)4 
1. Minimum inhibitory concentration (MIC) is in µg/mL with standard deviations in 
parenthesis. 
2. P ≤ 0.01 relative to WT 
3. P ≤ 0.01 relative to WT pBAD18Km 
4. P ≤ 0.01 relative to ∆leuO pBAD18Km 
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4.2.2 LeuO regulates expression of the carRS two-component regulatory system. 
Preliminary RNA sequencing analysis comparing WT and a ∆leuO mutant identified carRS as a 
potential target for LeuO regulation. Given that a carR mutant has previously been shown to be 
highly susceptible to polymyxin B (116), this provided a potential mechanism for which LeuO 
regulated polymyxin B resistance. To validate the preliminary data, we introduced the carRS-
lacZ plasmid pMH53 into WT strain JB58, ∆leuO strain XBV222, and ∆toxRS strain DT733. 
The resulting strains were then cultured in LB broth and assayed for β-galactosidase activity. The 
results showed that carRS-lacZ expression was increased ~40% in the ∆leuO mutant compared 
to WT (Fig. 12). In the ∆toxRS mutant, carRS-lacZ expression was comparable to the ∆leuO 
mutant. This was expected as ToxR is a positive regulator of leuO expression. This data would 
indicate that LeuO was a repressor of carRS expression and supported the hypothesis that LeuO 
regulated polymyxin B resistance through carRS. 
 Our lab has previously shown that leuO expression is induced in the presence of bile and 
the bile salt deoxycholate in a ToxR-dependent manner (101). It has also previously been found 
that carRS expression is repressed in the presence of bile and the bile salt deoxycholate (116). To 
determine if carRS repression in the presence of deoxycholate was dependent on LeuO, WT 
strain JB58, ∆leuO strain XBV222, and ∆toxRS strain DT733 carrying the carRS-lacZ plasmid 
were grown in LB broth containing 0.05% deoxycholate and assayed for β-galactosidase activity. 
Consistent with the previous published data, the results showed that carRS-lacZ expression was 
decreased >2-fold in the presence of deoxycholate compared to LB broth alone in the WT strain 
(Fig. 12). In contrast to this, the ∆leuO and ∆toxRS mutants displayed a ~2-fold increase in 
carRS-lacZ expression in the presence of deoxycholate compared to LB broth. Taken together 
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Figure 12. Expression of carRS is repressed by deoxycholate in a LeuO-dependent manner. 
V. cholerae WT strain JB58, ∆leuO mutant strain XBV222, and ∆toxRS mutant strain DT733 carrying the carRS-
lacZ reporter plasmid pMH53 were cultured in LB broth in the presence or absence of 0.05% deoxycholate (DOC) 
to stationary phase before being assayed for β-galactosidase activity as described in the Materials and Methods. The 
presented data is the mean +/- SD of two to three independent experiments. 
 
4.2.3 LeuO acts directly on the carRS promoter.  
The above reporter assays suggested that LeuO regulated carRS expression. However, it was 
unclear whether LeuO acted directly or indirectly at the carRS promoter. To address this, we 
tested the effect of leuO overexpression on transcription of the carRS promoter in a heterologous 
host. We introduced pBAD33 or pBAD33-leuO and the carRS-lacZ reporter plasmid pVA289 
into E. coli. We then cultured the cells in the presence of varying concentrations of arabinose 
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before quantifying carRS-lacZ expression using a β-galactosidase assay. The results showed that 
the addition of arabinose to the cells containing the empty vector (pBAD33) did not affect 
carRS-lacZ expression (Fig. 13A). However, there was an arabinose dose-dependent reduction in 
carRS-lacZ expression in the cells containing pBAD33-leuO. This suggested that LeuO may 
directly repress carRS transcription. As a control, we also tested whether toxRS overexpression 
affected carRS expression. The results showed that the addition of arabinose to cells containing 
pBAD33-toxRS did not affect carRS-lacZ expression, thus confirming the specificity of leuO for 
the carRS promoter. These results suggested that LeuO acts directly at the carRS promoter; 
however, we noted the possibility that LeuO could be affecting carRS expression via an 
intermediate gene that is conserved in E. coli and V. cholerae. 
To test whether LeuO functioned directly at the carRS promoter we performed 
electrophoretic mobility shift assays (EMSAs) using purified LeuO-MBP and the carRS 
promoter as previously described (119). Incubation of LeuO-MBP with a DNA probe covering 
the carRS promoter resulted in a mobility shift in the carRS probe starting at 2.5 μM (Fig. 13B 
lane 2). The carRS probe was further shifted at higher concentrations of LeuO-MBP (lanes 4 and 
5), which may suggest LeuO oligomerization on the carRS promoter. The idea of LeuO forming 
oligomers is consistent with findings in Salmonella enterica serovar Typhi where LeuO has been 
shown to form tetramers (121). In contrast, incubation of the carRS probe with purified MBP did 
not result in a mobility shift, indicating that LeuO-MBP binding was due to LeuO and not due to 
non-specific binding by the MBP. Incubation of LeuO-MBP with a DNA probe derived from the 
vexR promoter did not result in a mobility shift indicating that LeuO binding was specific for the 
carRS promoter. The collective results of these experiments support the conclusion that LeuO 




Figure 13. LeuO acts directly on the carRS promoter. 
(A) E. coli carrying either pBAD33, the pBAD33-leuO plasmid pVA126, or the pBAD33-toxRS plasmid pXB302 
and the carRS-lacZ plasmid pVA289 were grown in LB broth plus the indicated amount of arabinose to mid-
logarithmic phase and assayed for β-galacatosidase activity as outlined in the Materials and Methods. The data 
presented is the average +/- standard deviation of three independent experiments. Statistical analysis was conducted 
using two-way ANOVA with Tukey’s post-test *= p<0.0001. (B) Gel mobility shift assay. Biotin labeled DNA 
fragments carRS (1.5 nM) or vexR (3 nM) were incubated with LeuO-MBP at 0 μM in lane 1, 2.5 μM in lane 2, 5 
μM in lane 3, 10 μM in lane 4, 25 μM in lane 5, or MBP at 25 μM in lane 6. 
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4.2.4 V. cholerae survival in polymyxin B.  
The minimum inhibitory concentration data indicated that LeuO regulated polymyxin B 
susceptibility. To further investigate the role of LeuO in polymyxin B susceptibility we 
performed polymyxin B killing assays on WT, ∆leuO, ∆almE and ∆toxRS V. cholerae mutant 
strains. The cells were grown to middle logarithmic phase in LB broth before being incubated 
with a lethal dose of polymyxin B (500 µg/mL). We then assessed cell survival at 10 and 60 min 
by plating for viable cells. The results of the assay revealed that there was no significant 
difference between the rate of killing of the WT, ∆leuO and ∆toxRS mutants during the time 
course of this assay (Fig. 14A). The ∆leuO mutant did show a small increase in recovery in three 
of the four experiments relative to WT, but this difference did not meet the statistical 
significance threshold. By contrast, the ∆almE mutant was rapidly killed upon exposure to 
polymyxin B as evidenced by a ~3-log decrease in survival at 10 min and being unrecoverable at 
60 min. These latter results are similar to previous reports and are consistent with the proposed 
role of almE in polymyxin B resistance (116).  
In Fig. 12 we show that bile-dependent repression of carRS expression requires LeuO. 
Previous studies in our laboratory have shown that leuO transcription is upregulated upon 
exposure to bile salts and that LeuO contributed to bile salt resistance (101). This suggested the 
possibility that LeuO may contribute to polymyxin B and bile resistance in an inverse manner. 
To test whether bile salts affected V. cholerae survival upon exposure to lethal polymyxin B 
challenge, we repeated the above killing assays using V. cholerae cells that had been cultured in 
LB broth containing 0.05% deoxycholate. The WT results showed a ~1-log decrease in survival 
at 10 min and a >3-log decrease in survival at 60 min (Fig. 14B). By contrast, both the ∆leuO 
and ∆toxRS mutants did not exhibit a decrease in survival during the time course of the 
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experiment. The fact that the deoxycholate activates leuO expression and that the ∆leuO mutant 
was protected from the bactericidal activity of polymyxin B is consistent with the idea that LeuO 
is negatively regulating polymyxin B resistance in V. cholerae. Likewise, the ∆toxRS mutant was 
also protected and may be linked to its requirement for the upregulation of leuO expression by 
deoxycholate. Similar to cells grown in LB broth alone, the ∆almE mutant was rapidly killed by 





Figure 14. V. cholerae survival in polymyxin B. 
V. cholerae WT strain JB58, ∆leuO strain XBV222, ∆almE strain XBV302, and ∆toxRS strain JB461 were grown in 
(A) LB broth or (B) LB broth containing 0.05% deoxycholate to middle logarithmic phase. Strains were then 
exposed to a lethal concentration of polymyxin B for 10 or 60 min before aliquots were plated onto LB agar to 
quantify the viable cell counts as described in the Materials and Methods. The percent survival for each strain was 
calculated as (CFUoutput/CFUinput) x 100. The data presented is the average +/- standard deviation of four 
independent experiments. 
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4.3 DISCUSSION  
We have previously shown that leuO is regulated by ToxR, often in response to environmental 
signals. LeuO plays roles in resistance to environmental stressors, such as bile and acidity (101, 
119). Given that LeuO regulates antimicrobial resistance, we tested if LeuO affected the 
minimum inhibitory concentration of polymyxin B. We found that deletion of leuO resulted in 
increased polymyxin B resistance compared to WT (Table 5). This observed difference in was 
further found to be the result of LeuO regulating LPS remodeling through carRS. In this study, 
we show that LeuO is a repressor of carRS expression. Through EMSAs we were able to 
determine that LeuO directly binds to the carRS promoter (Fig. 13). Through reporter assays we 
found that carRS is repressed by deoxycholate in a LeuO-dependent manner (Fig. 12). 
During the course of infection V. cholerae is exposed to diverse environments depending 
on its location in the intestine. Cells that localize to the lumen are certainly exposed to high 
concentrations of bile salts. By contrast, cells that have traversed the mucosa to colonize the 
epithelial surface are somewhat protected from luminal bile salts due to the barrier properties of 
the mucous layer, but more likely to be exposed to high concentrations of cationic antimicrobial 
peptides that are produce by Paneth cells. We have previously shown that leuO expression was 
induced in response to bile salts and contributed to V. cholerae resistance to the antimicrobial 
effects of these anionic detergent-like molecules. These findings, combined with the data present 
in this report suggesting that LeuO indirectly regulates almEFG, suggest a model where LeuO 
differentially regulates resistance to cationic antimicrobial peptides and anionic bile salts in 
response to environmental cues.  
To test this model we performed polymyxin B killing assays on V. cholerae following 
growth in the presence or absence of the bile acid deoxycholate. Deoxycholate has been 
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previously shown to induce the expression of leuO during growth in LB broth. We hypothesize 
that growth of V. cholerae in deoxycholate will result in leuO activation and decreased 
expression of carRS and its downstream target almEFG. Downregulation of almEFG will result 
in LPS that is more negatively charged and increased polymyxin B susceptibility. We found that 
pre-adapting cells in the bile salt deoxycholate did not affect subsequent susceptibility to 
polymyxin B in the WT strain (Fig. 14B). This would suggest that the initial decreased 
concentration of CarRS in the cell does not keep it from mounting a proper tolerance response to 
polymyxin B. This may suggest that the activator of carRS in response to polymyxin B is a able 
to displace LeuO from the carRS promoter. In contrast, ∆leuO and ∆toxRS mutants displayed 
significantly increased survival to polymyxin B when grown in the presence of deoxycholate. 
This was not observed in the ∆almE mutant, suggesting that this mechanism is dependent upon 
AlmE. The observed increase in polymyxin B resistance in the ∆leuO and ∆toxRS mutants may 
be attributed to an elevated concentration of CarRS in the cell prior to polymyxin B exposure.  
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5.0  CONCLUSIONS 
The success of V. cholerae as a human pathogen is dependent upon its ability to rapidly sense 
and adapt to changes in its growth environment. In vivo this includes adaptation to the dynamic 
environments V. cholerae encounters during passage through the host gastrointestinal tract. In 
this work we show that LeuO functions downstream of ToxR to regulate a number of adaptive 
responses that may be important in pathogenesis including bile resistance, acid tolerance, and 
cationic antimicrobial peptide resistance. 
5.1 THE LEUO REGULON 
Transcriptome profiles of global regulators, like members of the LTTR family, can provide 
insight into their contributions to pathogenesis, metabolism, and cell division. The transcriptome 
profiles of LTTRs have been applied to vaccine development and for the treatment and diagnoses 
of bacterial infections (49). To better understand how LeuO regulates diverse cellular responses 
in V. cholerae, a goal of this proposal was to characterize the LeuO regulon in V. cholerae. To 
identify target genes of LeuO, RNA sequencing (RNAseq) analysis was used. LeuO was found 
to regulate the expression of 113 genes in the V. cholerae genome with the majority of the 
regulated genes being repressed (Appendix B). These genes were involved in diverse functions 
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including pathogenesis, metabolism, biofilm production, and stress responses. The gene targets 
identified will help to provide insight into the function of LeuO in future studies.  
 The considerable number of genes regulated by LeuO in V. cholerae was not surprising 
given that LeuO has been shown to be a global regulator in both S. enterica serovar 
Typhimurium and E. coli. LeuO has been characterized as functioning as an antagonist of the 
repressor H-NS in the Enterobacteriaceae (47, 48). Comparison of the LeuO regulon to the 
recently published V. cholerae H-NS regulon as identified by RNAseq data analysis (122), 
suggests that this is not conserved in V. cholerae. In contrast, it appears that LeuO functioned as 
a repressor at many H-NS suppressed genes including genes in the ToxR regulon. This suggests 
that LeuO may augment H-NS or alternatively be redundant for H-NS in V. cholerae. 
One interesting observation from our RNAseq data is that a number of the genes 
identified as targets of LeuO in V. cholerae were horizontally acquired, such as the vibrio 
pathogenicity island and the superintegron that is unique to El Tor strains. Horizontally acquired 
genes are often maintained because they encode genes that enhance virulence or fitness and 
typically encode their own regulator. Additional LeuO targets include accessory colonization 
factors, the toxins MARTX and hemolysin, and a number of proteases involved in host escape 
and predator evasion. Taken together this indicates that LeuO regulation of pathogenesis extends 
far beyond the role it plays in CT and TCP production. 
5.2 LEUO AND ADAPTIVE RESPONSES 
Our results show that LeuO is a member of the ToxR regulon and that ToxR activates leuO 
expression in response to environmental cues. We have shown that the environmental cues can 
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be derived exogenously or endogenously (Section 2.2.2 and (43)). Exogenous molecules include 
components of bile, while endogenous molecules include cyclic peptides. Other endogenous 
molecules appear to be products of cell metabolism. This latter conclusion is based on the 
observation that deletion or inhibition of the V. cholerae RND efflux systems results in 
upregulation of leuO (unpublished); a phenotype that appears to be linked to the intracellular 
accumulation of molecules in the RND negative background that are normally removed from the 
cell by the RND efflux systems. Once leuO is activated by its effector molecules, LeuO then 
regulates genes that contribute to adaptive responses. In this work we have conclusively shown 
that leuO contributes to acid tolerance (Chapter 3), bile resistance (Chapter 2), and cationic 
antimicrobial peptide resistance (Chapter 4). However, based on our RNAseq data (Appendix B), 
we suspect that leuO may also regulate other genes late in infection, when the cells are at high 
cell density in the intestinal lumen, which contribute to dissemination and transmission 
phenotypes that have been observed in human shed V. cholerae. Based on our collect work with 
LeuO, we propose two models to explain the contributions of LeuO to V. cholerae pathogenesis.  
 In the first model we posit that LeuO is modulating adaptive responses based on spatial 
localization within the small intestine; whether the cell is localized to the lumen or the surface of 
the epithelium (Fig. 15). We hypothesize that following ingestion V. cholerae is exposed to 
organic acids and bile in the lumen of the intestine. These molecules are sensed by ToxR which 
results in activation of leuO expression (Section 2.2.2). LeuO then functions to activate genes 
that contribute to bile resistance while downregulating the carRS and almEFG genes. The 
downregulation of the latter genes in essence increases the net negative charge of the 
lipopolysaccharide (LPS). This increase in the negative charge results in electrostatic repulsion 
of anionic bile salts and makes the cell more resistant to the bactericidal effects of bile. By 
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contrast, we predict that leuO expression will be reduced in cells that have traversed the mucous 
layer, which has been shown to function as a diffusion barrier for bile salts (123). The down 
regulation of leuO results in derepression of carRS and increased almEFG expression (Section 
4.2.2). The increase in almEFG expression will then result in glycine modification of LPS which 
will result in a net decrease in the negative charge of LPS. The decrease in LPS negative charge 
will then result in increased resistance to cationic antimicrobial peptides (CAMPs) that are 
predicted to be present at elevated concentrations at the epithelial surface. Future studies using a 




Figure 15. Putative model for V. cholerae leuO expression in the small intestine. 
(A) V. cholerae containing a chromosomal leuO-gfp reporter are indicated by the comma shaped bacteria. Following 
V. cholerae ingestion, bile that is present in the intestinal lumen induces leuO expression which imparts a bile 
resistance phenotype. As V. cholerae migrates to the epithelial cell surface it traverses the mucus layer that acts as a 
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diffusion barrier to bile salts. V. cholerae penetrating the mucosa will thus be exposed to ever lessening 
concentrations of bile salts. This leads to a gradient of leuO expression based on the cells location in the mucus layer 
with the lowest expression being observed in V. cholerae cells localized to the epithelial surface. The repression of 
leuO expression at the epithelial surface results in deprepression of carRS and upregulation of almEFG which 
imparts resistance to cationic antimicrobial peptides (CAMP) that produce by cells localized to the epithelium and at 
maximal concentration near the epithelial surface. (B) leuO expression in V. cholerae localized to the intestinal 
lumen. Cells in the lumen are exposed to bile which induces leuO expression. LeuO then represses carRS while 
activating genes that contribute to bile resistance. (C) leuO expression in V. cholerae localized to the intestinal 
epithelium. The mucous layer acts as a bile diffusion barrier. This results in downregulation of leuO and 
upregulation of carRS and its target genes almEFG. The net result is glycinylation of LPS which imparts resistance 
to CAMP. 
 
In addition to the spatial regulation based on location in the intestinal tract, we also 
speculate that LeuO is involved in regulation of genes late in the infection cycle. LeuO is a 
stationary phase protein and has been shown to be induced late in infection in the infant mouse 
model (43). Late in infection, the ToxR regulon is repressed before dissemination (18, 19), and 
we have shown that LeuO is a ToxR regulon repressor. Further, ToxR responds to cFP, a small 
molecule that accumulates in the growth media, which repressed virulence factor production in a 
leuO-dependent manner (43). Taken together, these observations suggest a second model for 
leuO during pathogenesis (Fig. 16). In this model we hypothesize that leuO functions to regulate 
genes late in infection that contribute to both V. cholerae dissemination into the aquatic 
ecosystem and transmission to a new host. We speculate that cell metabolites accumulate when 
V. cholerae is at high cell density. These metabolites signal through ToxR to activate leuO 
expression. LeuO then downregulates virulence factor production while activating the expression 
of genes that contribute to survival and persistence in the aquatic ecosystem (e.g. biofilm) and 
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genes that contribute to hyperinfectivity that is transiently observed in human shed V. cholerae 
(9, 20).  
 
 
Figure 16. Putative model for the relationship between cell metabolites and leuO expression. 
(A) At low cell density or early during infection the concentration of cell metabolites are low and ToxR functions 
with TcpP to activate the expression of the ToxR regulon which facilitates colonization and disease development. 
(B) Late in infection V. cholerae grows to high cell titers in the lumen. Nutrients become limiting and the 
concentration of cellular metabolites increases. The metabolites interact with the periplasmic sensing domain (PPD) 
of ToxR, which results in ToxR upregulating the expression of leuO. LeuO then represses virulence factor 
production while upregulating the expression of other genes that contribute to late infection phenotypes affecting 
dissemination and transmission. 
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APPENDIX A 
MATERIALS AND METHODS 
A.1 STRAINS, CHEMICALS, AND MEDIA 
The bacterial strains used are listed in Tables 1, 3 & 4. E. coli strains EC100λpir and SM10λpir 
were used for cloning and plasmid mobilization, respectively. E. coli strains EC100λpir or 
BW25113 were used for the two plasmid β-galactosidase reporter assays. E. coli strain ER2566 
was used for purification of LeuO-MBP and MBP. The V. cholerae strains used in these studies 
were seventh pandemic O1 El Tor clinical isolates. V. cholerae strain JB58 (N16961∆lacZ SmR) 
(124) or strain XBV144 (C6706 ∆lacZ SmR) were used as the wild-type (WT) control strains. 
Bacterial strains were grown at 37°C in Luria-Bertani (LB) broth or on LB agar. AKI growth 
conditions which are used to induce the ToxR regulon have been described previously (125). 
Modified T-media was prepared as previously described (40). Stock solutions of the detergents 
and bile (Difco Oxgall) were made in water and filter sterilized before use. An organic acid 
cocktail (1X) consisting of: 87 mM acetic acid, 25 mM butyric acid, and 37 mM propionic acid 
was used for the organic acid challenge assays. Acid adaptation media contained 0.1X organic 
acid cocktail in LB broth at pH 5.7. Bacterial stocks were maintained at -80°C in LB broth 
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containing 25% glycerol. Growth media was supplemented with carbenicillin (Cb) and 
streptomycin (Sm) at 100 µg/ml, kanamycin (Km) at 50 µg/ml, or chloramphenicol (Cm) at 1 
µg/ml for V. cholerae or at 25 µg/ml for E. coli as required. Arabinose was added to growth 
media at the indicated concentrations to induce expression from the arabinose-regulated 
promoter in pBAD18, pBAD18Km and pBAD33. 
A.2 PLASMID AND MUTANT CONSTRUCTION 
Plasmids and oligonucleotides used are listed in Tables 1, 3 & 4. Genomic DNA from 
N16961∆lacZ SmR was used as a PCR template for cloning. Plasmid reporters containing 
derivatives of the leuO promoter lacking one or both ToxR binding sites were constructed as 
follows. pVA258 (PleuO lacking the distal ToxR binding site) was generated by PCR using the 
PleuO1-F and PleuO-R oligonucleotide primers. The resulting amplicon was digested with BamHI 
and XmaI restriction endonucleases and ligated into similarly digested pTL61T. pVA261 (PleuO 
lacking both ToxR binding sites) was generated by PCR using the PleuO2-F and PleuO-R primers. 
The resulting PCR amplicon was digested with BamHI and XmaI restriction endonucleases and 
ligated into similarly digested pTL61T. The cadC-lacZ reporter plasmid pXB239 was 
constructed as follows. Briefly, the PcadC-F/PcadC-R PCR primer pair was used to amplify the 
cadC promoter region from the V. cholerae N16961 genome. The resulting PCR amplicon was 
then digested with XhoI and XbaI restriction endonucleases before being ligated into similarly 
digested pTL61T to generate pXB239. The β-galactosidase reporter construct pVA289 for 
carRS-lacZ was generated as follows. The PCR primers PcarRS-F/PcarRS-R were used to amplify 
the carRS promoter region from the V. cholerae N16961 genome. The resulting PCR amplicon 
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was digested with XhoI and BamHI restriction endonucleases before being ligated into similarly 
digested pTL61T to create pVA289. The β-galactosidase reporter construct pMH53 for carRS-
lacZ was generated as follows. The PCR primers PcarRS-short-F/PcarRS-short-R were used to 
amplify the carRS promoter region from the V. cholerae N16961 genome. The resulting PCR 
amplicon was digested with XhoI and BamHI restriction endonucleases before being ligated into 
similarly digested pTL61T to create pMH53. 
The leuO expression plasmid pVA94 (pBAD18::leuO) was constructed by moving leuO 
from pXB298 as a NheI and XbaI restriction fragment into the same sites in pBAD18. The leuO 
expression plasmid pVA126 (pBAD33::leuO) was constructed by removing the leuO fragment 
from pXB298 using XbaI and SspI restriction enzymes. The resulting ~1 kb leuO fragment was 
collected and ligated into pBAD33 digested with XbaI and SmaI. pXB302 (pBAD33::toxRS) was 
made by moving the toxRS genes from pXB289 as a SacI and SphI restriction fragment into the 
same sites in pBAD33. pDT1391 (pBAD33::toxRΔppdS) was made by moving the toxRΔppdS genes 
from pXB286 as a SacI and SmaI restriction fragment into the same sites in pBAD33.  
pWM91::∆toxRppd, which contains a 94 amino acid C-terminal deletion of the ToxR 
periplasmic domain, was made by crossover PCR as previously described (126, 127). Briefly, 
primer pairs toxRΔppd-F1/toxRΔppd-R2 and toxRΔppd-F2/toxRΔppd-R1 were used in separate PCR 
reactions with N16961 genomic DNA. The resulting ~1 kb amplicons were collected and used as 
the template for second round PCR amplification with the flanking toxRΔppd-F1/toxRΔppd-R1 PCR 
primers. The resulting ~2 kb amplicon was then digested with SacI and SmaI restriction 
endonucleases before being ligated into similarly digested pWM91. The aphB deletion plasmid, 
pWM91::∆aphB, was also constructed by PCR stitching. The aphB-F1/aphB-R2/ and aphB-
F2/aphB-R1 PCR primer pairs were used to amplify ~1 kb regions flanking aphB. The resulting 
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PCR amplicons were used as the template for a second round of PCR using the aphB-F1 and 
aphB-R1 PCR primers. The resulting ~2 kb amplicon was digested with BamHI and SacI 
restriction endonucleases before being ligated into similarly digested pWM91 to generate 
pWM91::∆aphB. The almE (VC1579) deletion plasmid pWM91::∆almE was made by crossover 
PCR. Primer pairs almE-F1/almE-R2 and almE-F2/almE-R1 were used in separate PCR 
reactions with N16961 chromosomal DNA. The resulting ~1 kb amplicons were purified and 
used as templates in a second PCR amplification with the flanking almE-F1/almE-R1 PCR 
primers. The resulting ~2 kb amplicon was then digested with SacI and SmaI restriction 
endonucleases before being ligated into similarly digested pWM91 to generate pWM91::∆almE . 
Deletion of the ToxR periplasmic domain in V. cholerae strain SS4 was accomplished as 
follows. pWM91::∆toxRppd was conjugated into JB58 and plasmid cointegrants were selected for 
Sm and Cb resistance. Sm and Cb resistant cointegrants were then plated onto LB agar plates 
containing 5% sucrose and no NaCl. Sucrose resistant and Cb sensitive colonies were then 
screened by PCR using toxRΔppd-F1/toxRΔppd-R1 primers to confirm deletion of the ToxR 
periplasmic domain. Verification of toxR∆ppd in SS4 was accomplished by DNA sequencing of 
the toxR locus. Deletion of V. cholerae aphB (VC1049) was performed by allelic exchange as 
previously described (63). Briefly, E. coli SM10λpir was used to conjugate plasmid 
pWM91::∆aphB into V. cholerae JB58 and co-integrants were selected for Sm/Cb resistance. 
Several Sm/Cb resistant colonies were cultured on LB agar (without NaCl) containing 5% 
sucrose to select for resolution of the integrated plasmid. Sucrose resistant and Cb sensitive 
colonies were then screened by PCR using the aphB-F1/aphB-R1 PCR primers to confirm aphB 
deletion. To make a V. cholerae almE deletion mutant, pWM91::∆almE was conjugated into 
JB58 and plasmid co-integrants were selected for resistance to Sm and Cb. Several Sm and Cb 
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resistant co-integrants were then plated onto LB agar (without NaCl) plates containing 5% 
sucrose. Sucrose resistant and Cb sensitive colonies were then screened by PCR using almE-
F1/almE-R1 primers to confirm deletion of almE. This resulted in the identification of strain 
XBV302 which was further verified by DNA sequencing of the almE locus. Deletion of lacZ 
(VC2338) in JB804 was accomplished in an identical manner using pDLT to generate strain 
XBV144. Deletion of leuO (VC2485) in XBV144 was accomplished as previously described to 
generate strain VA412 (59). The C6706 transposon insertion mutants were graciously supplied 
by Dr. John Mekalanos (Harvard Medical School). 
The LeuO-MBP purification plasmid pVA175 (pMAL-c2::leuO) was constructed by 
amplifying the leuO gene from N16961 using the LeuO-F/LeuO-R PCR primers. The resulting 
PCR amplicon was then digested with XbaI and SmaI restriction endonucleases and ligated to 
pMAL-c2 which had been restricted with XbaI and XmnI endonucleases to generate pVA175. 
This ligation resulted in a translational fusion of leuO to the C-terminus of malE (maltose 
binding protein). The DNA sequence of the protein purification construct was subsequently 
verified by sequencing. 
A.3 REPORTER ASSAYS 
β-galactosidase assays were performed as follows. V. cholerae strains carrying the leuO-lacZ 
reporter indicated in the figure legend were cultured overnight in LB broth at 37°C with shaking. 
The cultures were then diluted 1:100 into fresh LB broth and incubated at 37°C with shaking. 
Culture aliquots were collected in triplicate at mid-exponential phase (OD600 of ~0.5) to quantify 
β-galactosidase activity as previously described (128). V. cholerae strains harboring the cadC-
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lacZ reporter plasmid pXB239 were grown under AKI conditions and culture aliquots were taken 
in triplicate at various times to quantify β-galactosidase activity. The effect of LeuO on cadC 
expression in V. cholerae consisted of growing strain JB58 containing the cadC-lacZ plasmid 
pXB239 and pBAD33-leuO plasmid pVA126 under AKI conditions in the presence or absence 
of 0.02% arabinose. Culture aliquots were collected in triplicate after 5 hrs to quantify cadC-lacZ 
expression. The effect of LeuO on aphB expression in V. cholerae was accomplished by growing 
strain JB58 containing the aphB-lacZ plasmid pXB203 and the pBAD33-leuO plasmid pVA126 
under AKI conditions in the presence or absence of 0.02% arabinose. Culture aliquots were 
collected in triplicate after 5 hrs to quantify aphB-lacZ expression. V. cholerae strains carrying 
the leuO-lacZ reporter plasmid pXB266 or the carRS-lacZ reporter plasmid pMH53 were 
cultured overnight in LB broth at 37°C with shaking. The cultures were then diluted 100-fold 
into fresh LB broth containing 0.05% deoxycholate, 10 mM CaCl2, or 5 µg/mL polymyxin B and 
incubated at 37°C with shaking. Culture aliquots were then collected in triplicate at mid-
logarithmic phase (OD600 of ~0.5) or stationary phase (OD600 of ~1.0) to quantify β-galactosidase 
production. All of the reporter experiments were performed independently at least three times. 
Expression from the lacZ reporter was calculated and displayed as Miller Units (MU). 
The E. coli two plasmid β-galactosidase reporter experiments were performed as follows. 
E. coli strain EC100λpir bearing an expression plasmid (pBAD33, pXB302, or pDT1391) and a 
lacZ reporter plasmid (pXB266, pVA258, or pVA261) were cultured overnight in LB broth with 
shaking at 37°C. The overnight cultures were then diluted 1:100 into fresh LB broth plus or 
minus 0.08% arabinose and the cultures were incubated at 37°C with shaking. Culture aliquots 
were collected in triplicate at mid-exponential phase (OD600 of ~0.5) to quantify β-galactosidase 
activity as previously described (128). LeuO repression of cadC expression in E. coli was 
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accomplished as follows. Overnight cultures of E. coli strain BW25113 containing the cadC-lacZ 
plasmid pXB239 and the pBAD33-leuO plasmid pVA126 were diluted 1:100 in LB broth plus or 
minus 0.02% arabinose. The cultures were incubated at 37°C with shaking and aliquots were 
collected after 5 hrs to quantify cadC-lacZ expression using β-galactosidase activity. E. coli 
strain EC100λpir containing an expression plasmid (pBAD33, pVA126, or pXB302) and the 
carRS-lacZ reporter plasmid pVA289 was cultured overnight in LB broth with shaking at 37°C. 
The overnight cultures were then diluted 100-fold into fresh LB broth containing 0%, 0.005%, 
0.01%, or 0.05% arabinose and the cultures were incubated at 37°C with shaking. Culture 
aliquots were collected in triplicate at mid-exponential phase (OD600 of ~0.5) to quantify β-
galactosidase activity. Expression from the reporter plasmids was calculated and displayed as 
Miller Units (MU). 
The bioluminescence assays were performed as follows. V. cholerae strain JB58 
containing pJB906 (leuO-lux) was cultured overnight in LB broth at 37°C with shaking. The 
overnight cultures were then diluted 1:100 into fresh LB broth and incubated at 37°C with 
shaking for two hours. Aliquots (100 μl) of the culture were then diluted into 100 μl of LB broth 
plus the indicated substrates (i.e. DMSO, DOC or cFP) and distributed into triplicate wells of a 
white 96-well microtiter plate with a clear bottom (Corning). In these experiments DOC was 
used at 0.0125%, cFP at 1 mM and DMSO at 0.1%. The plates were then incubated at 37°C and 
luminescence and the OD600 were measured at the indicated time points using a BioTek Synergy 
HT plate reader. The relative light units (RLU) for each sample were calculated by dividing the 
luminescence by the OD600. The reported results are the average and standard deviation of three 
independent experiments. 
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A.4 PURIFICATION OF LEUO-MBP AND MBP 
Proteins for the gel shift assays were purified as follows. E. coli ER2566 carrying plasmid 
pMAL-c2 or the pMAL-c2::leuO plasmid pVA175 were grown in LB broth overnight at 37°C 
with aeration. The cultures were then diluted 100-fold into LB broth containing Cb and 
incubated at 37°C with shaking to an OD600 ~0.5 when 0.3 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) was added and the cultures were incubated for an additional 2 hrs. 
The cells were then harvested by centrifugation and the pellet resuspended in column buffer (20 
mM Tris-HCl, 200 mM NaCl, 1 mM EDTA) plus 1 mM phenylmethylsulfonyl fluoride. The 
cells were then lysed with a M-11P Microfluidizer according to the manufacturer’s instructions 
(Microfluidics). The resulting cell lysates were cleared of particulate matter by centrifugation at 
15,000 x g for 20 min at 4°C. The clarified supernatant (i.e. LeuO-MBP or MBP) was then 
diluted 1:6 with column buffer and loaded onto a 0.8 x 7.0 cm chromatography column 
containing 1 ml of amylose resin (New England Biolabs). The column was equilibrated with 12 
ml of column buffer before the clarified supernatant was run through. Bound proteins were 
eluted from the resin using elution buffer (20 mM Tris-HCl, 200 mM NaCl, 1 mM EDTA, 10 
mM maltose). The purity of the eluted fusion proteins were analyzed by SDS–PAGE with 
Coomassie brilliant blue R-250 staining. Protein concentrations were determined using the 
Coomassie Plus (Bradford) Assay kit according to the manufacturer’s instructions (Thermo 
Scientific). 
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A.5 MEMBRANE ISOLATION 
V. cholerae DT733 (∆toxRS) containing pXB289 (pBAD18::toxRS), pXB286 
(pBAD18::toxR∆ppdS), or pBAD18 was cultured in LB broth with shaking at 37°C to an OD600 of 
~1.0 when expression from the arabinose promoter was induced by the addition of arabinose to 
0.2%. The cultures were then incubated with shaking at 37°C for an additional hour when the 
cells were harvested by centrifugation. The cell pellet was resuspended in 10 mM Tris-HCl (pH 
8.0) in 0.75 M sucrose. Spheroplasts were then induced by the addition of 150 μg/ml lysozyme 
followed by the addition of 2 volumes of buffer A (10 mM Tris-HCl, pH 8.0, 10 mM EDTA) 
(129, 130). The cells were then lysed by passage through a model M-11P Microfluidizier 
(Microfluidics). Particulate matter was removed from the cell lysate by centrifugation at 8,000 x 
g for 10 minutes at 4°C. The membrane containing supernatant was then subjected to 
centrifugation in a SW-28 rotor (Beckman) at 24,000 rpm at 4°C for 2 hours to pellet the 
membrane fraction. The membrane pellet was then suspended in 20% sucrose in buffer B (10 
mM Tris-HCl, pH 8.0, 1 mM EDTA) and applied to a two-step 60% and 70% sucrose gradient. 
The sucrose gradients were then subjected to centrifugation in a SW-28 rotor at 23,000 rpm at 
4°C for 18 hours. The inner and outer membrane fractions were then decanted from the sucrose 
gradients and diluted with two volumes of cold buffer B before being centrifuged in a Ti55 rotor 
(Beckman) at 47,000 rpm at 4°C for 1 hour. The resulting inner membrane pellets were 
resuspended in cold buffer B and frozen at -20°C until used. Protein concentrations were 
determined using the Pierce Coomassie Plus Protein Assay according to the manufacturer’s 
directions. 
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A.6 ELECTROMOBILITY SHIFT ASSAY 
The following is for the EMSA in Chapter 2 using membrane fractions. DNA probes for gel shift 
assays were generated by PCR using the primers listed in Table 1. The PCR primers for the 
EMSAs were engineered to include a 5’ tail (5’GCGGGAGTCGGCAGCG 3’) which facilitated 
biotinylation of the probes by a second PCR reaction using the 5’BIO PCR primer which 
hybridized to the 5’ tail. The 5’BIO PCR primer was purchased from the manufacturer (IDT) 
with a 5’ biotin label. The biotinylated probes were gel purified and quantified using a NanoDrop 
2000 spectrophotometer (Thermo Scientific) before being used in the EMSAs. The DNA binding 
reactions were performed in a final volume 10 μl of binding buffer (10 mM Tris-HCl (pH 7.4), 5 
mM NaCl, 50 mM KCl, 1 mM EDTA, 50 μg/ml BSA, 1.5 nM biotinylated probe and 10 μg/ml 
sheared salmon sperm DNA) containing the indicated amounts of the V. cholerae inner 
membranes. The binding reactions were incubated at 30°C for 30 minutes before being subjected 
to electrophoresis at 150 V for 1 hour on a non-denaturing 5% polyacrylamide TBE gel that had 
been pre-run with 5% thioglycolic acid for 1 hour at 150 V in 1x TBE buffer. The resolved gels 
were electroblotted to positively charged nylon membrane in 0.5x TBE buffer at 380 mAmps for 
1 hour, before the nylon membrane was UV crosslinked at 120,000 microjoules using a 
Stratalinker 1800 Crosslinker (Strategene). The biotinylated probes were then detected using the 
Pierce Chemiluminescent Nucleic Acid Detection Module (Thermo Scientific) and visualized 
using a FluorChem E imaging system (Protein Simple). 
The following is for the EMSA in Chapter 3 using LeuO-MBP or MBP. The DNA 
fragments designated cadC1 (the nucleotide sequence between -79 and +1 relative to the cadC 
transcriptional start site) and cadC2 (the nucleotide sequence between -8 to +77 relative to the 
cadC transcriptional start site) were PCR amplified from the N16961 genome using the cadC-
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EMSA-F1/cadC-EMSA-R1 and cadC-EMSA-F2/cadC-EMSA-R2 oligonucleotide primers, 
respectively (Table 3). The PCR fragments were then gel purified and 100 ng was used as a 
template for a second PCR reaction using the biotinylated 5’BIO oligonucleotide primer 
purchased from Integrated DNA Technologies (Coralville, IA). The resulting DNA fragments 
were end labeled with biotin. The biotin labeled probes (1.5 nM) were incubated with purified 
LeuO-MBP or MBP in amounts ranging from 0 to 30 μM in binding buffer containing 10 mM 
Tris (pH 7.4), 150 mM KCl, 0.1 mM dithiothreitol, 0.1 mM ethylenediaminetetraacetic acid (pH 
8.0), and 200 μg/ml sheared salmon sperm. The binding reactions were incubated at room 
temperature for 20 min before being subjected to electrophoresis on a non-denaturing 5% TBE-
PAGE in 0.25x TBE buffer at 200 V for 45 min. The DNA in the gel was transferred to a nylon 
membrane in 0.5x TBE buffer at 380 mAmps for 1 hr. The nylon membrane was then UV 
crosslinked at 120,000 microjoules using a Stratalinker 1800 (Stratagene). Biotin labeled DNA 
was detected using the Chemiluminescent Nucleic Acid Detection Module (Thermo Scientific) 
and visualized using a Fluorchem E Digital Darkroom imager (Protein Simple). 
The following is for the EMSA in Chapter 4 using LeuO-MBP or MBP. The vexR DNA 
fragment was previously defined and consisted of the nucleotide sequence between -129 and -46 
relative to the vexR translational start site (74). The DNA fragment containing the carRS 
promoter (the nucleotide sequence between -400 to +20 relative to the carR translational start 
site) was PCR amplified from the N16961 genome using carRS-F-EMSA and carRS-R-EMSA 
oligonucleotide primers (Table 4). The resulting PCR fragment was then gel purified and 100 ng 
was used as a template for a second PCR reaction using the biotinylated 5’BIO oligonucleotide 
primer purchased from IDT to produce the end-labelled DNA probe. The biotin labeled probes 
(carRS 1.5 nM, vexR 3 nM) were incubated with purified LeuO-MBP or MBP in amounts 
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ranging from 0 to 25 μM in binding buffer containing 10 mM Tris (pH 7.4), 150 mM KCl, 0.1 
mM DTT, 0.1 mM EDTA (pH 8.0), and 200 μg/mL sheared salmon sperm. The 10 μl binding 
reactions were incubated at room temperature for 20 min before being subjected to 
electrophoresis on a non-denaturing 5% TBE-PAGE gel in 0.25x TBE buffer at 200V for 45 
min. The gel was pre-run at 100V for 1 hr in 0.25x TBE prior to sample addition. The DNA in 
the gel was then transferred to a nylon membrane in 0.5x TBE buffer at 380 mAmps for 1 hr. 
The nylon membrane was then UV crosslinked at 120,000 microjoules using Stratalinker 1800 
(Stratagene) before the biotin labeled DNA fragments were detected using Chemiluminescent 
Nucleic Acid Detection Module (Thermo Scientific) and visualized using FluorChem E (Protein 
Simple). 
A.7 LYSINE DECARBOXYLASE ASSAYS 
Strains were grown in AKI media static at 37°C until the cultures reached an OD600 of ~0.1 (4 
hrs). Strains containing pBAD18Km-leuO were grown in AKI media in the presence or absence 
of 0.02% arabinose. After 4 hrs, culture aliquots were collected and processed for the 
quantification of lysine decarboxylase activity as previously described with slight modification 
(131). Briefly, the cells were collected by centrifugation and normalized to an OD600=1. The cell 
pellet was then washed with 1 ml of cold (4°C) Buffer A (1 M NaCl, 0.05 M Potassium Pi buffer 
pH 6.5) before being centrifuged and resuspended in 200 μl cold (4°C) Buffer B (20 mM 
Potassium Pi pH 5.8). 20 μl of CHCl3 was then added to each sample followed by vortexing for 
15 sec to disrupt the cell membrane. Quantification of lysine decarboxylase activity was then 
carried out in triplicate by combining 10 μl of the cell lysate with 110 μl prewarmed Buffer C (5 
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mM lysine, 0.1 mM pyridoxal 5`-phosphate, 16 mM Potassium Pi pH 5.8); a parallel mixture 
without lysine was also prepared to control of the level of endogenous polyamines, since these 
react in the assay as cadaverine. The enzymatic reaction was incubated at 37°C for 15 min before 
adding 120 μl of Stop Solution (1 M Na2CO3) and placing on ice. Lysine and cadaverine were 
then derivatized by adding 120 μl of 10 mM 2,4,6-Trinitrobenzene sulphonate to the mixture and 
incubating at 40°C for 4 min. After incubation, samples were chilled on ice. For phase 
separation, 1 ml toluene was added and thoroughly vortexed for 20 sec; N,N`-
bistrinitrophenylcadaverine (TNP-cadaverine) is soluble in toluene and N,N`-
bistrinitrophenyllysine (TNP-lysine) is toluene insoluble. Samples were then centrifuged at 2,000 
rpm for 5 min to allow the phases to separate. The concentration of TNP-cadaverine was 
measured by removing the upper aqueous phase and reading the A340 in quartz cuvettes with a 
Genesys 10S UV-Vis spectrophotometer (Thermo Scientific). Lysine decarboxylase activity was 
determined as the difference in A340 between the sample incubated with lysine and that incubated 
without. Specific activity, was calculated using the equation (A340/(time x OD600)) x 1000, and is 
a measure of lysine converted to cadaverine per time in min per cell density. 
A.8 BILE KILLING ASSAYS 
Overnight cultures of the indicated strains were diluted 1:100 in LB broth plus or minus 0.1% 
arabinose (to induce expression from pBAD18) and incubated at 37°C with shaking for four 
hours. Culture aliquots were then collected and washed once with phosphate buffered saline 
(PBS) before being diluted in PBS to an OD600 of 0.5. Serial dilutions of each strain were then 
plated onto LB agar plates to enumerate the cell titer at time zero (CFUinput). Aliquots containing 
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~106 CFU of each strain were then added to PBS containing 10% bile (toxR mutant strains) or 
20% bile (toxR positive strains); the bile concentrations were reduced for the toxR mutant strains 
due to their increased bile sensitivity. The cultures were then incubated statically at room 
temperature for 60 minutes when aliquots were collected, washed in PBS, and plated onto LB 
agar to quantify the viable cells (CFUoutput). The recovery ratio of each strain was then calculated 
as the (CFUoutput/CFUinput). The fold change in recovery was then determined by dividing the 
recovery ratio for the mutant strains by the recovery ratio for WT. Fold change in recovery for 
the leuO overexpressing strain was determined by dividing the recovery ratio for 
∆toxRS::pBAD18-leuO by the recovery ratio for ∆toxRS::pBAD18. The presented data are the 
mean and SD of three independent experiments. Statistical significance was determined using 
Dunnett Multiple Comparisons Test relative to a recovery ratio of 1.0. 
A.9 ORGANIC ACID CHALLENGE ASSAYS 
The acid challenge assays were facilitated by obtaining mutant strains from an ordered V. 
cholerae C6706 transposon library (104). C6706 is highly conserved with N16961 differing by 
only 87 single nucleotide polymorphisms across the entire genome (132) and we have not 
observed differences in the LeuO regulon or acid tolerance between the two strains. Overnight 
cultures of each test strain were diluted 1:10,000 into 10 ml of AKI broth, in the presence or 
absence of 0.2% arabinose, in a test tube and incubated statically at 37°C for 4 hrs before the 
cultures were normalized to OD600=0.1 before use. The analysis of unadapted cells was 
performed as follows. Aliquots (100 μl) of the respective normalized cultures were distributed 
into the wells of a 96-well microtiter plate that contained a linear range of the organic acid 
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cocktail in LB broth. For the acid adaptation analysis, the cells were resuspended in organic acid 
adaptation media at pH 5.7 and incubated for 1 hr at 37°C. The cells were then collected by 
centrifugation and resuspended in fresh LB broth from which 100 μl aliquots were distributed 
into the wells of a 96-well microtiter plate that contained a linear range of the organic acid 
cocktail in LB broth. The inoculated microtiter plates were then incubated at 37°C and ~10 μl 
aliquots from each well were replica plated at the indicated time points onto LB agar plates using 
a 96-pin replicator. The agar plates were then incubated at 37°C for 18 hrs when the agar plates 
were imaged using a Fluorchem E Digital Darkroom imager (Protein Simple). 
A.10 ANTIMICROBIAL SUSCEPTIBILITY ASSAYS 
Antimicrobial susceptibility assays were performed using gradient agar plates as previously 
described (64). The gradient agar plates were inoculated with saturated overnight cultures of the 
V. cholerae WT strain JB58, ∆leuO strain XBV222, ∆almE strain XBV302, and ∆toxRS strain 
JB461 and incubated overnight at 37°C. For strains bearing pBAD18Km or pBAD18Km-leuO 
0.1% arabinose was included in the gradient agar plate. After overnight incubation, growth of 
each strain across the gradient was measured. The minimum inhibitory concentration (MIC) of 
each strain was calculated as the percent of growth across the plate multiplied by the 
antimicrobial concentration used in the plate. The presented results are the mean and standard 
deviation of three independent biological replicates. Statistical significance for the tested strains 
was determined using one sample student’s t-tests.  
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A.11 POLYMYXIN B KILLING ASSAYS 
Overnight cultures of the V. cholerae WT strain JB58, ∆leuO strain XBV222, ∆almE strain 
XBV302, and ∆toxRS strain JB461 were diluted 100-fold into fresh LB broth plus or minus 
0.05% deoxycholate. The inoculated cultures were then incubated with aeration at 37°C until 
they reached an OD600 of ~0.5 (4 hrs). Culture aliquots were subsequently collected by 
centrifugation and pellets resuspended in phosphate buffered saline (PBS) to an OD600 of 0.1. 
Serial dilutions of each strain were then plated onto LB agar plates to enumerate the cell titer at 
time zero (CFUinput). The remaining cells were then collected by centrifugation and resuspended 
in LB broth containing 500 μg/mL polymyxin B and incubated at 37°C with aeration. Aliquots 
were then collected at 10 and 60 min, washed in PBS, and plated onto LB agar to quantify the 
viable cells (CFUoutput). The percent survival of each strain was then calculated by dividing the 
number of cells recovered following 10 min or 60 min exposure to polymyxin B by the number 
of cells in the input at time zero (CFUoutput/CFUinput) x 100. The reported data represents the 
average +/- standard deviation from four independent experiments.  
A.12 RNA EXTRACTION AND QRT-PCR 
RNA was extracted from V. cholerae cultures grown in modified T-media at 37°C with shaking 
to an OD600 of ~0.3 when NRES (50 mM) or bile (0.2%) was added to the cultures. The cultures 
were then incubated for an additional 15 minutes at 37°C with shaking before RNA was 
extracted using Trizol according to the manufacturer’s instructions (Ambion). The resulting 
RNA was quantified using a Nanodrop spectrophotometer (Thermo) before being used to make 
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cDNA with the Maxima First Strand cDNA synthesis kit (Life Technologies) according to the 
manufacturer’s instructions. The resulting cDNA was then used with gene specific primers 
(Table 1) and the SYBR Green PCR master mix (Thermo) to quantify gene expression using a 
StepOnePlus Real-Time PCR System (Applied Biosystems). The relative gene expression levels 
were then calculated by the 2(-∆∆CT) method (133) using the A-subunit of DNA gyrase (gyrA) as 
an internal control. The presented results are the mean +/- standard deviation of three 
independent biological replicates, with each biological replicate being generated from at least 





B.1 INTRODUCTION AND RESULTS 
To better define the target genes that LeuO regulates, we preformed RNAseq analysis to 
determine the LeuO transcriptome. Total RNA was isolated from WT and ∆leuO mutant strains 
grown in LB broth containing bile. This condition was chosen as it would show a significant 
difference in LeuO production using physiologically relevant parameters. In the WT strain, bile 
will induce leuO expression ~6-fold and in the ∆leuO mutant no LeuO will be present. Given 
that both the WT and ∆leuO mutant were treated the same, bile-responsive genes will not be 
identified as changing expression unless regulated through LeuO. Analysis of the RNAseq 
transcriptome data indicated that 113 genes were regulated by LeuO: 33 genes upregulated, 80 
genes downregulated (Table 6). The genes included in Table 6 were selected with the criteria of 
having a 2-fold change and p value <0.05. The fold change listed is the difference in WT 
compared to a ∆leuO mutant, therefore repression by LeuO denoted as a positive number and 
decimals indicate activation by LeuO. 
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name Function Putative Role 
2.28 1.00E-04 VC0280 cadB cadaverine/lysine antiporter acid tolerance and metabolism 
3.00 <1.00E-05 VC0281 cadA lysine decarboxylase, inducible acid tolerance and metabolism 
2.66 <1.00E-05 VC0284   putative outer membrane iron receptor iron transport 
0.42 <1.00E-05 VC0481 lysE Transport and binding proteins metabolism 
0.32 2.00E-04 VC0606 glnB-1 nitrogen regulatory protein PII  regulatory protein 
2.56 0.0089 VC0612   cellobiose/cellodextrin-phosphorylase chitin catabolism 
3.12 0.0085 VC0613 chb-1 beta-N-acetylhexosaminidase chitin catabolism 
3.80 0.0037 VC0614   conserved hypothetical protein  chitin catabolism 
2.35 0.0031 VC0615   endoglucanase-related protein chitin catabolism 
4.14 <1.00E-05 VC0616   peptide ABC transporter, ATP-binding protein chitin catabolism 
3.06 <1.00E-05 VC0617   peptide ABC transporter, ATP-binding protein chitin catabolism 
2.85 <1.00E-05 VC0618   peptide ABC transporter, permease protein chitin catabolism 
2.79 <1.00E-05 VC0619   peptide ABC transporter, permease protein chitin catabolism 
2.38 <1.00E-05 VC0620 cbp 
peptide ABC transporter, periplasmic peptide-binding 
protein chitin catabolism 
0.18 <1.00E-05 VC0687  cstA carbon starvation protein A stringent response 
2.49 <1.00E-05 VC0715 frp nitroreductase A metabolism 
2.60 2.00E-04 VC0734 aceB malate synthase A  metabolism 
0.38 0.0189 VC0770   conserved hypothetical protein   
11.01 <1.00E-05 VC0796 citC citrate (pro-3S)-lyase ligase  fermentation 
18.13 <1.00E-05 VC0797 citD citrate lyase, gamma subunit  fermentation 
11.74 0.0492 VC0798 citE citrate lyase, beta subunit  fermentation 
12.26 0.0319 VC0799 citF citrate lyase, alpha subunit  fermentation 
10.66 0.0287 VC0800 citX 
apo-citrate lyase phosphoribosyl-dephospho-CoA 
transferase fermentation 
0.45 0.0453 VC0802   hypothetical protein   
3.03 <1.00E-05 VC0829 tcpB toxin co-regulated pilus biosynthesis protein B pathogenesis 
2.27 <1.00E-05 VC0831 tcpC 
toxin co-regulated pilus biosynthesis outer membrane 
protein C pathogenesis 
1.99 0.0189 VC0833 tcpD toxin co-regulated pilus biosynthesis protein D pathogenesis 
9.56 <1.00E-05 VC0838 toxT TCP pilus virulence regulatory protein  pathogenesis 
8.47 <1.00E-05 VC0839 tcpJ leader peptidase  pathogenesis 
9.92 <1.00E-05 VC0840 acfB accessory colonization factor  pathogenesis 
7.98 <1.00E-05 VC0841 acfC accessory colonization factor  pathogenesis 
5.14 <1.00E-05 VC0842  conserved hypothetical protein  pathogenesis 
6.97 <1.00E-05 VC0843 tagE-1 TagE protein  pathogenesis 
2.52 0.0245 VC0844 acfA accessory colonization factor  pathogenesis 
0.37 0.0489 VC0910 treB PTS system, trehalose-specific IIBC components trehalose metabolism 
0.36 0.0317 VC0911 treC trehalose-6-phosphate hydrolase trehalose metabolism 







name Function Putative Role 
2.70 3.00E-04 VC1295   c-di-GMP phosphodiesterase degrade c-di-GMP  
2.42 <1.00E-05 VC1319 carS sensor histidine kinase  
biofilm and polymyxin B 
resistance 
2.79 <1.00E-05 VC1320 carR DNA-binding response regulator  
biofilm and polymyxin B 
resistance 
0.46 <1.00E-05 VC1321   hypothetical protein   
2.01 <1.00E-05 VC1444 vpsV hypothetical protein biofilm 
2.16 <1.00E-05 VC1445 vpsS sensor histidine kinase/response regulator biofilm 
3.40 2.00E-04 VC1449 rtxH hypothetical protein pathogenesis 
2.59 <1.00E-05 VC1454 rstA1 RstA1 protein  pathogenesis 
2.61 <1.00E-05 VC1463 rstA2 RstA2 protein  pathogenesis 
2.70 0.012 VC1542 ligA-2 DNA ligase  
DNA replication, 
recombination and repair 
0.41 <1.00E-05 VC1560 katG catalase/peroxidase  oxidative stress 
2.21 <1.00E-05 VC1561   transcriptional regulator, LysR-family  regulatory protein 
2.05 0.0245 VC1562   beta-lactamase-related protein/Zn-dependent hydrolase   
0.33 1.00E-04 VC1581   NADH dehydrogenase subunit L metabolism 
2.05 0.0187 VC1583 sodC superoxide dismutase, Cu-Zn  oxidative stress 
4.13 <1.00E-05 VC1585 katB catalase oxidative stress 
8.63 <1.00E-05 VC1644   hypothetical protein   
5.69 <1.00E-05 VC1709   zinc protease protease 
2.55 0.0053 VC1947   transcriptional regulator, LysR-family  regulatory protein 
2.44 <1.00E-05 VC2240   phenolic acid decarboxylase metabolism 
4.41 <1.00E-05 VC2370  sensory box/GGDEF family protein  synthesize c-di-GMP 
0.39 <1.00E-05 VC2373 gltB-1 glutamate synthase, large subunit biosynthesis of glutamate 
0.42 <1.00E-05 VC2374 gltD-1 glutamate synthase, small subunit biosynthesis of glutamate 
4.69 <1.00E-05 VC2388   hypothetical protein 
 
3.99 0.0188 VC2621 xds extracellular nuclease-related protein  extracellular nuclease 
0.36 <1.00E-05 VCA0014 malQ 4-alpha-glucanotransferase maltose biosynthesis 
0.44 0.0116 VCA0023   hypothetical protein   
2.29 <1.00E-05 VCA0035   phosphatidylglycerophosphatase B phospholipid degradation 
4.41 <1.00E-05 VCA0044   hypothetical protein, predicted periplasmic protease protease 
2.23 6.00E-04 VCA0101   conserved hypothetical protein   
3.18 1.00E-04 VCA0139   
hypothetical protein, putative acetyl CoA synthase 
homolog    
0.40 <1.00E-05 VCA0148   TagA-related protein  protease 
2.80 <1.00E-05 VCA0160 mtr tryptophan-specific transport protein  tryptophan metabolism 
3.95 <1.00E-05 VCA0161 tnaA tryptophanase  tryptophan metabolism 
2.03 2.00E-04 VCA0163   conserved hypothetical protein    
2.89 0.0188 VCA0195   hypothetical protein   
2.87 0.0033 VCA0218 tlh thermolabile hemolysin  pathogenesis 







name Function Putative Role 
5.16 0.0032 VCA0223 prtV protease  protease, predator protection 
31.96 <1.00E-05 VCA0250 amy1 alpha-amylase metabolism 
2.15 0.0085 VCA0267 emrD-3 multidrug resistance protein D multidrug resistance 
13.59 <1.00E-05 VCA0344   hypothetical protein   
9.30 <1.00E-05 VCA0345   conserved hypothetical protein   
3.81 <1.00E-05 VCA0346   H-REV 107-related protein    
9.43 <1.00E-05 VCA0428   hypothetical protein   
5.03 <1.00E-05 VCA0431   hypothetical protein   
2.15 <1.00E-05 VCA0432   hypothetical protein   
0.35 <1.00E-05 VCA0447   haemagglutinin associated protein  pathogenesis 
8.86 <1.00E-05 VCA0448   hypothetical protein   
0.34 <1.00E-05 VCA0536   conserved hypothetical protein    
0.22 <1.00E-05 VCA0556   hypothetical protein   
2.13 1.00E-04 VCA0565   sensor histidine kinase  regulatory protein 
2.69 <1.00E-05 VCA0612 mscL large-conductance mechanosensitive channel osmotic shock protection 
0.46 0.0089 VCA0641   conserved hypothetical protein    
3.79 0.0086 VCA0650   hypothetical protein   
0.49 0.0089 VCA0688 phaC polyhydroxyalkanoic acid synthase  phospholipid metabolism 
0.41 0.0111 VCA0690   acetyl-CoA acetyltransferase  phospholipid metabolism 
0.26 0.0103 VCA0691   acetoacetyl-CoA reductase  phospholipid metabolism 
2.18 <1.00E-05 VCA0721   hypothetical protein   
0.46 <1.00E-05 VCA0728   hypothetical protein integron unique to El Tors 
0.42 <1.00E-05 VCA0729   hypothetical protein integron unique to El Tors 
0.45 <1.00E-05 VCA0730   hypothetical protein integron unique to El Tors 
3.83 0.0031 VCA0748 glpB anaerobic glycerol-3-phosphate dehydrogenase subunit B glycerol metabolism 
3.65 2.00E-04 VCA0749 glpC anaerobic glycerol-3-phosphate dehydrogenase subunit C glycerol metabolism 
2.56 0.0016 VCA0834   hypothetical protein   
0.40 2.00E-04 VCA0860 malS alpha-amylase metabolism 
2.49 <1.00E-05 VCA0862 fadL-3 long-chain fatty acid transport protein  transport  
2.18 <1.00E-05 VCA0863 volA lipase, putative  phospholipid degradation 
0.38 3.00E-04 VCA0934   hypothetical protein 
 
0.28 <1.00E-05 VCA0943 malG maltose ABC transporter, permease protein maltose metabolism 
0.38 2.00E-04 VCA0944 malF maltose ABC transporter, permease protein maltose metabolism 
0.28 <1.00E-05 VCA0945 malE 
maltose ABC transporter, periplasmic maltose binding 
protein maltose metabolism 
0.25 4.00E-04 VCA0952 vpsT  transcriptional regulator, LuxR-family  biofilm 
0.21 <1.00E-05 VCA1028 ompS maltoporin, cell envelope OMP maltose metabolism 




B.2.1 RNA Isolation 
V. cholerae strains used in this study are listed in Table 1. Overnight cultures of V. cholerae 
strains JB58 (WT) and XBV222 (∆leuO) were diluted 100-fold into fresh LB broth containing 
0.05% crude bile (oxgall). Cultures were incubated at 37°C with aeration to an OD600 of ~0.5 
before RNA was extracted using Trizol according to the manufacturer’s instructions (Ambion). 
The resulting RNA was treated with DNase and further purified on an RNeasy column according 
to the manufacturer’s directions (Qiagen). RNA was quantified using a Nanodrop 
spectrophotometer (Thermo) before being sent for RNAseq experiments. Three individual 
biological replicates of each strain were used for RNA isolation and subsequently sent for 
RNAseq experiments.  
B.2.2 Whole-transcriptome analysis with total RNA sequencing 
Total RNA from each sample was assessed using Qubit 2.0 fluorometer and Agilent TapeStation 
2200 for RNA quantity and quality. Total RNA libraries were generated using Illumina TruSeq 
Stranded Total RNA Sample Preparation Guide Rev. E. The first step involved the removal of 
ribosomal RNA (rRNA) using biotinylated, target-specific oligos combined with Ribo-Zero 
rRNA removal beads depleting samples of both cytoplasmic and mitochondrial rRNA, Gram-
positive and Gram-negative bacterial RNA. Following purification, the RNA was fragmented 
using divalent cations under elevated temperature. The cleaved RNA fragments were copied into 
first strand cDNA using reverse transcriptase and random primers, followed by second strand 
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cDNA synthesis using DNA polymerase I and RNase H. These cDNA fragments then have the 
addition of a single 'A' base and subsequent ligation of the adapter. The products were purified 
and enriched with PCR to create the final cDNA library.  
The cDNA libraries were validated using KAPA Biosystems primer premix kit with 
Illumina-compatible DNA primers and Qubit 2.0 fluorometer. Quality was examined using 
Agilent Tapestation 2200. The cDNA libraries were pooled at a final concentration 1.8 pM. 
Cluster generation and 75 bp paired read single-indexed sequencing was performed on Illumina 
NextSeq 500. 
B.2.3 Analysis Methods 
Sequencing analysis was done using Bacterial RNA-seq Analysis on Maverix Analytic Platform 
(Maverix Biomics, Inc, San Mateo, CA). Raw sequencing reads from Illumina sequencing 
platform that was converted into FASTQ file format were quality checked for potential 
sequencing issues and contaminants using FastQC. Adapter sequences, primers, Ns, and reads 
with quality score below 28 were trimmed using fastq-mcf of ea-utils and Trimmomatic. Reads 
with a remaining length of fewer than 20 bp after trimming were discarded. Pre-processed reads 
were mapped to the Vibrio cholerae genome (RefSeq Accession Number: NC_002505 and 
NC_002506) using EDGE-pro. Read counts for RefSeq genes generated by EDGE-pro were 
normalized across all samples and then used for differential expression analysis using DEseq. 





% : percent 
:: : insertion 
~ : approximately 
+/- : plus/minus 
°C : degree centigrade 
β : beta 
Δ : deletion 
A : absorbance 
AKI : growth conditions which are used to induce the ToxR regulon 
AMP : antimicrobial peptide 
ANOVA : analysis of variance 
bp : base pair 
cAMP : cyclic AMP production 
CAMP : cationic antimicrobial peptide 
Cb : carbenicillin 
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cDNA : complementary DNA 
cFP : cyclo(Phenylalanine-Proline) 
CFU : colony forming units 
Cm : chloramphenicol 
CT : cholera toxin 
DMSO : dimethyl sulfoxide 
DNA : deoxyribonucleic acid 
DOC : deoxycholate 
DTT : Dithiothreitol 
e.g. : exemplī grātiā ; latin for “for example” 
E. coli : Escherichia coli 
EDTA : Ethylenediaminetetraacetic acid 
EMSA : Electromobility shift assay 
g : gravitational acceleration 
gfp : green fluorescence protein 
GM1 : monosialotetrahexosyl ganglioside 
hr : hour 
H-NS : histone-like nucleoid structuring protein 
i.e. : id est; latin for “that is” 
IPTG : Isopropyl β-D-1-thiogalactopyranoside 
kb : kilo bases 
Km : kanamycin 
lacZ : in reference to the β-galactosidase gene 
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LB : Luria-Bertani 
LPS: lipopolysaccharide 
LTTRs : LysR-type transcriptional regulators 
lux : in reference to the luciferase operon 
M : molar 
mA : milli Amps 
MBP : maltose binding protein 
µg : micro gram 
MIC : minimum inhibitory concentration 
min : minutes 
mL : milli liter 
µL : micro liter 
MU : Miller Units 
NCBI : National Center for Biotechnology Information 
ng : nano gram 
nm : nano meter 
nM : nano Molar 
NR : not recovered 
NRES : asparagine, arginine, glutamic acid, and serine 
OD : optical density 
OD600 : optical density at 600 nano meters 
OMP : outer membrane protein 
P : P value 
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PAGE : Polyacrylamide gel electrophoresis 
PBS : phosphate buffered saline 
PCR : polymerase chain reaction 
pH : measurement of acidity/alkalinity of an aqueous solution 
ppd : periplasmic domain 
qRT-PCR : quantitative real time polymerase chain reaction 
RLU : relative light units 
R : resistance 
RNA : ribonucleic acid 
RNAseq : RNA sequencing 
RND : Resistance-Nodulation-Cell Division family 
rpm : revolutions per minute 
S. enterica : Salmonella enterica 
SD : standard deviation 
SDS : sodium dodecyl sulfate 
Sm : streptomycin 
TBE : Tris/Borate/EDTA 
TCP : Toxin co-regulated pilus 
TX-100 : Triton X-100 
U : units 
V : volts 
V. cholerae : Vibrio cholerae 
WT : wild type 
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